| Symbol | MOLN |
|---|---|
| Name | MOLECULAR PARTNERS AG |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 8952 Switzerland Wagistrasse 14 |
| Telephone | +41 44 755 7700 |
| Fax | — |
| — | |
| Website | https://www.molecularpartners.com |
| Incorporation | CH |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: SIX Swiss Exchange |
| CIK | 0001745114 |
| Description | Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The companys product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. Additional info from NASDAQ: |
2026-05-12 20:00
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
Read more
2026-05-12 20:00
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
Read more
2026-05-04 05:00
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
Read more
2026-05-04 05:00
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
Read more
2026-05-01 11:00
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
Read more
2026-05-01 11:00
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
Read more
2026-04-19 16:00
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
Read more
2026-04-19 16:00
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02715843 | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgk… | — | Non-Hodgkin's B-cell Lymphoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02961491 | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Re… | — | Pheochromocytoma | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00214448 | Reproducibility of the Array-Based Comparative Genomic Hybridization (aCGH) Sys… | — | Genetic Disorders | Unknown | — | — | ClinicalTrials.gov |
| NCT00733798 | A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Ma… | Phase1 | Melanoma | Terminated | — | — | ClinicalTrials.gov |
| NCT07593079 | Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and… | Phase2 | Prostate Cancer | Not_Yet_Recruiting | 2026-06-30 | 2027-09-30 | ClinicalTrials.gov |
| NCT07285993 | Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Nov… | Phase2 | Breast Cancer | Not_Yet_Recruiting | 2026-06-01 | 2027-12-30 | ClinicalTrials.gov |
| NCT07551531 | GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial | — | Kidney Transplant | Not_Yet_Recruiting | 2026-06-01 | 2033-06-01 | ClinicalTrials.gov |
| NCT07570667 | Global Longitudinal Health Monitoring and Blood Sample Collection Study to Prom… | — | CVD | Not_Yet_Recruiting | 2026-05-01 | 2048-05-29 | ClinicalTrials.gov |
| NCT07357909 | Safety Study of Intravenous Hydrogen-Oxygen Ultrafine Bubbles in Adults | Phase1 | Healthy Volunteer | Not_Yet_Recruiting | 2026-05-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT07278479 | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell … | Phase1 | Large Cell Neuroendocrine Carcinoma | Recruiting | 2026-04-01 | 2032-09-01 | ClinicalTrials.gov |
| NCT06734156 | CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorec… | — | Colorectal Cancer (CRC) | Recruiting | 2026-03-02 | 2029-12-02 | ClinicalTrials.gov |
| NCT06189924 | Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients | — | Acute Respiratory Failure | Recruiting | 2026-03-01 | 2029-12-31 | ClinicalTrials.gov |
| NCT07024316 | A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Les… | Phase1 | Congenital Erythropoietic Porphyria (CEP) | Recruiting | 2026-01-29 | 2028-06-01 | ClinicalTrials.gov |
| NCT07036380 | MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patie… | Phase2 | Advanced Biliary Tract Carcinoma | Recruiting | 2025-12-22 | 2029-11-01 | ClinicalTrials.gov |
| NCT07158905 | AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980) | Phase1 | Alzheimer Disease | Not_Yet_Recruiting | 2025-12-15 | 2029-10-15 | ClinicalTrials.gov |
| NCT07157891 | Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Co… | Early_Phase1 | Osteoarthritis (OA) | Not_Yet_Recruiting | 2025-12-10 | 2028-12-11 | ClinicalTrials.gov |
| NCT07020806 | [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive… | Phase1 | Metastatic Lobular Breast Carcinoma | Recruiting | 2025-11-18 | 2027-06-01 | ClinicalTrials.gov |
| NCT07142278 | DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau | Phase1 | Alzheimer Disease | Not_Yet_Recruiting | 2025-11-01 | 2027-07-31 | ClinicalTrials.gov |
| NCT07178678 | Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Mode… | Phase2 | Mild Alzheimer's Disease | Not_Yet_Recruiting | 2025-11-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT06790394 | Test-retest Study With [18F]FBB in Cardiac Amyloidosis | Phase1 | Cardiac Amyloidosis | Recruiting | 2025-10-21 | 2026-09-01 | ClinicalTrials.gov |
| NCT07530809 | Time-restricted Feeding in MASLD | Na | Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD) | Recruiting | 2025-10-15 | 2029-05-15 | ClinicalTrials.gov |
| NCT07000708 | VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle | Na | Vaccination | Recruiting | 2025-09-10 | 2027-01-01 | ClinicalTrials.gov |
| NCT07060716 | Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Moni… | — | Kidney Transplant Rejection | Recruiting | 2025-09-08 | 2025-12-01 | ClinicalTrials.gov |
| NCT07064759 | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascu… | Phase3 | Neovascular Age-Related Macular Degeneration (nAMD) | Recruiting | 2025-07-22 | 2029-02-01 | ClinicalTrials.gov |
| NCT07033091 | Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility… | Na | Oropharynx Cancer | Recruiting | 2025-06-01 | 2031-03-30 | ClinicalTrials.gov |
| NCT06905028 | Exploratory Clinical Study on Fasting in Psoriasis and Psoriatic Arthritis (Ris… | Na | Psoriasis Arthritis | Recruiting | 2025-04-30 | 2026-06-01 | ClinicalTrials.gov |
| NCT06526299 | Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patien… | Phase2 | Metastatic Castration-Resistant Prostate Carcinoma | Recruiting | 2025-04-29 | 2027-12-31 | ClinicalTrials.gov |
| NCT07422090 | Preventing Suicide With Digital Phenotyping and Pharmacogenetics-Based Interven… | — | Suicide Attempt | Recruiting | 2025-04-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT06864988 | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Mac… | Phase3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | Active_Not_Recruiting | 2025-03-03 | 2028-06-01 | ClinicalTrials.gov |
| NCT06770907 | Genetic Carbohydrate Maldigestion As Model to Study Food Hypersensitivity Mecha… | — | Sucrase Isomaltase Deficiency | Not_Yet_Recruiting | 2025-03-01 | 2026-03-01 | ClinicalTrials.gov |
| NCT06622616 | NUTRITIONAL INTERVENTION STUDY to EVALUATE the EFFECT of ACHETA DOMESTICUS POWD… | Na | Insulin Resistance | Not_Yet_Recruiting | 2025-01-01 | 2027-11-01 | ClinicalTrials.gov |
| NCT06975436 | Performance Study of the Cobas® BV/CV Test on Samples From Participants With an… | — | Bacterial Vaginosis | Completed | 2024-12-30 | 2025-06-30 | ClinicalTrials.gov |
| NCT06490536 | The Sagittarius Trial | Phase3 | Colon Cancer Stage II | Recruiting | 2024-10-22 | 2028-09-01 | ClinicalTrials.gov |
| NCT06623032 | Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acy… | Na | Medium-chain Acyl-CoA Dehydrogenase Deficiency | Recruiting | 2024-10-18 | 2027-09-01 | ClinicalTrials.gov |
| NCT06672692 | A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Ass… | Na | Influenza a | Recruiting | 2024-09-30 | 2025-05-01 | ClinicalTrials.gov |
| NCT06369220 | A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for M… | Na | Chlamydia Trachomatis Infection | Completed | 2024-07-29 | 2025-05-28 | ClinicalTrials.gov |
| NCT06148792 | A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria | Phase3 | Vivax Malaria | Recruiting | 2024-05-10 | 2027-03-01 | ClinicalTrials.gov |
| NCT06741293 | Improving Colorectal Cancer Early Screening in Portugal: Identification of Gut … | — | Colorectal Cancer Screening | Recruiting | 2023-11-28 | 2029-11-28 | ClinicalTrials.gov |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients W… | Phase1 | Non Small Cell Lung Cancer | Terminated | 2023-11-01 | 2024-10-31 | ClinicalTrials.gov |
| NCT05412706 | Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response Afte… | Phase2 | Metastatic Colorectal Cancer | Withdrawn | 2023-09-04 | 2023-09-04 | ClinicalTrials.gov |
| NCT05930561 | 4D-150 in Patients With Diabetic Macular Edema | Phase2 | Diabetic Macular Edema | Active_Not_Recruiting | 2023-08-09 | 2029-02-28 | ClinicalTrials.gov |
| NCT05897515 | LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical … | Na | Influenza A | Completed | 2023-06-19 | 2023-10-31 | ClinicalTrials.gov |
| NCT06016569 | Study of Early Cancer Biomarkers in Breath Condensate in Population of Individu… | Na | Lung Cancer | Recruiting | 2023-06-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT07112937 | The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells:… | — | Rectal Cancer Patients | Recruiting | 2023-05-02 | 2027-12-31 | ClinicalTrials.gov |
| NCT05910372 | Tools for the Differential Diagnosis of Fibromyalgia Based on Cognitive Tasks | — | Fibromyalgia | Completed | 2023-04-25 | 2023-12-01 | ClinicalTrials.gov |
| NCT05043701 | Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma | Early_Phase1 | Recurrent Glioblastoma | Recruiting | 2023-03-01 | 2026-02-01 | ClinicalTrials.gov |
| NCT05516628 | Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to… | Phase2 | Hepatocellular Carcinoma | Recruiting | 2023-02-28 | 2027-03-01 | ClinicalTrials.gov |
| NCT05642429 | Study of AV-1959D, an Amyloid Beta Vaccine | Phase1 | Alzheimer Disease | Active_Not_Recruiting | 2023-02-27 | 2026-11-07 | ClinicalTrials.gov |
| NCT05490576 | Tau And Connectomics In TES Study | Phase1 | Chronic Traumatic Encephalopathy | Unknown | 2023-02-03 | 2024-12-31 | ClinicalTrials.gov |
| NCT05698654 | Fasting-mimicking Diet and Longevity Diet, Body Composition and Aging | Na | Overweight | Unknown | 2023-01-30 | 2025-01-30 | ClinicalTrials.gov |
| NCT05184088 | Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis | Phase3 | Cardiac Amyloidosis | Recruiting | 2023-01-13 | 2026-03-01 | ClinicalTrials.gov |
| NCT06758817 | The Triad of Nutrition, Intestinal Microbiota and Rheumatoid Arthritis (TASTY) | Na | Diet Interventions | Recruiting | 2023-01-02 | 2025-12-31 | ClinicalTrials.gov |
| NCT05642897 | Mind Programme for Women With Breast Cancer | Na | Breast Cancer Female | Recruiting | 2023-01-02 | 2025-08-31 | ClinicalTrials.gov |
| NCT05703997 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Pro… | Phase2 | Small Cell Lung Carcinoma | Not_Yet_Recruiting | 2023-01-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT05673057 | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase1 | Leukemia | Recruiting | 2022-12-29 | 2029-12-01 | ClinicalTrials.gov |
| NCT05582538 | Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cance… | Phase2 | Triple Negative Breast Cancer Metastatic | Recruiting | 2022-12-15 | 2029-12-01 | ClinicalTrials.gov |
| NCT05641688 | [18F]PI-2620 Phase 3 Histopathological Study | Phase3 | Alzheimer Disease | Recruiting | 2022-12-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT06037993 | Endocannabinoid Activity Remodulation for Psychosis Liability in Youth | Na | Clinical High Risk for Psychosis | Unknown | 2022-11-01 | 2025-11-01 | ClinicalTrials.gov |
| NCT05629559 | 4D-310 in Adults With Fabry Disease and Cardiac Involvement | Phase1 | Fabry Disease | Recruiting | 2022-10-16 | 2030-06-01 | ClinicalTrials.gov |
| NCT05552521 | Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants | — | Diastolic Dysfunction | Completed | 2022-09-20 | 2024-02-26 | ClinicalTrials.gov |
| NCT05444790 | Abbott NxTekTM Malaria RDT WHO Prequalification Study | — | Malaria | Completed | 2022-06-30 | 2023-07-30 | ClinicalTrials.gov |
| NCT05475210 | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroe… | Phase1 | Neuroendocrine Tumors | Unknown | 2022-06-18 | 2025-03-30 | ClinicalTrials.gov |
| NCT05774561 | Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring | — | Cervical Cancer | Recruiting | 2022-06-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05173727 | Prevalence and Serotype of Streptococcus Pneumoniae Hospitalized Adult With Com… | — | Pneumonia, Bacterial | Completed | 2022-05-15 | 2023-11-01 | ClinicalTrials.gov |
| NCT05344937 | Validation Study of Uromonitor in High Risk Microhematuria Patients | — | Bladder Cancer | Unknown | 2022-05-02 | 2024-05-01 | ClinicalTrials.gov |
| NCT05343611 | Chocolate and Physical Exercise to Reduce Malnutrition in Pre-dementia Aged Peo… | Na | Dementia | Unknown | 2022-05-01 | 2024-12-30 | ClinicalTrials.gov |
| NCT05248230 | 4D-710 in Adult Patients With Cystic Fibrosis | Phase2 | Cystic Fibrosis Lung | Recruiting | 2022-03-29 | 2031-06-01 | ClinicalTrials.gov |
| NCT05187546 | Test-retest Study With [18F]PI-2620 in PSP-RS and NDC | Phase1 | Progressive Supranuclear Palsy | Completed | 2022-03-10 | 2024-03-05 | ClinicalTrials.gov |
| NCT04223674 | Serological Screen and Treat Trial for Plasmodium Vivax | Na | Malaria, Vivax | Unknown | 2022-02-09 | 2023-12-30 | ClinicalTrials.gov |
| NCT05143528 | Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzhe… | Phase3 | Alzheimer Disease | Not_Yet_Recruiting | 2022-02-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT05032352 | Predictive Assay for Decision Making in Adjuvant Therapy | — | Carcinoma, Non-Small-Cell Lung | Terminated | 2022-01-28 | 2022-10-28 | ClinicalTrials.gov |
| NCT05084521 | Interest of Famotidine in Children With Sickle Cell Disease | Phase2 | Sickle Cell Disease | Completed | 2022-01-12 | 2022-12-12 | ClinicalTrials.gov |
| NCT04757090 | 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid… | Phase2 | HER2-positive Solid Tumor | Withdrawn | 2021-12-31 | 2023-12-31 | ClinicalTrials.gov |
| NCT05673837 | the Type ONe dIabetic Bone Collaboration Study | — | Osteoporosis Secondary | Unknown | 2021-12-10 | 2024-04-01 | ClinicalTrials.gov |
| NCT05197270 | 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | Phase1 | Neovascular (Wet) Age-Related Macular Degeneration | Recruiting | 2021-12-09 | 2031-01-01 | ClinicalTrials.gov |
| NCT05085301 | RapiGEN BIOCREDIT Malaria Ag RDTs WHO Prequalification Study | — | Malaria | Completed | 2021-12-01 | 2023-05-30 | ClinicalTrials.gov |
| NCT05098405 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refr… | Phase1 | Advanced Malignant Solid Tumor | Terminated | 2021-10-11 | 2024-01-19 | ClinicalTrials.gov |
| NCT05070637 | Circulating Tumor Cell Reducing No-touch Nephrectomy | Na | Renal Cell Carcinoma | Completed | 2021-09-27 | 2022-05-18 | ClinicalTrials.gov |
| NCT05096962 | COVID-19: SARS-CoV-2-CZ-PREVAL-II Study | — | COVID-19 | Completed | 2021-09-13 | 2022-02-24 | ClinicalTrials.gov |
| NCT03459547 | Soft Peri-implant Tissue Around Different Abutment Materials | Na | Dental Implant Failure Nos | Unknown | 2021-09-06 | 2021-12-01 | ClinicalTrials.gov |
| NCT04793750 | Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC) | Na | HIV Infections | Completed | 2021-08-18 | 2025-03-31 | ClinicalTrials.gov |
| NCT04698096 | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Metabol… | — | Metabolic Syndrome | Completed | 2021-07-20 | 2022-03-07 | ClinicalTrials.gov |
| NCT05294978 | EyeConic: Qualification for Cone-Optogenetics | — | Retinal Dystrophies | Recruiting | 2021-07-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05177640 | Biodistribution and Dosimetry of 99mTc-Duramycin | Phase1 | Healthy Volunteers | Completed | 2021-06-17 | 2021-12-14 | ClinicalTrials.gov |
| NCT05616559 | Precision Medicine in the Depression Treatment | — | Depressive Disorder, Major | Recruiting | 2021-06-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT05780463 | MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | Phase3 | COVID-19 | Completed | 2021-06-11 | 2023-06-08 | ClinicalTrials.gov |
| NCT05337774 | Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blas… | Phase1 | Mild Traumatic Brain Injury | Terminated | 2021-06-07 | 2022-04-30 | ClinicalTrials.gov |
| NCT04698122 | Establishment of the Human Intestinal and Salivary Microbiota Biobank- Diabetes | — | Type 1 Diabetes | Completed | 2021-05-27 | 2022-02-02 | ClinicalTrials.gov |
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Phase1 | Advanced Solid Tumor | Terminated | 2021-05-27 | 2024-10-31 | ClinicalTrials.gov |
| NCT04828161 | A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory A… | Phase2 | COVID-19 | Terminated | 2021-05-10 | 2022-01-27 | ClinicalTrials.gov |
| NCT04949282 | Spanish Series of Patients Treated With the Radionuclide Lutetium177 | — | Neuroendocrine Tumors | Recruiting | 2021-05-10 | 2035-12-31 | ClinicalTrials.gov |
| NCT04834856 | Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients | Phase2 | Covid19 | Completed | 2021-04-01 | 2021-08-20 | ClinicalTrials.gov |
| NCT04721613 | Circadian Melatonin Rhythms in Critically Ill Patients With Delirium | — | ICU Delirium | Completed | 2021-03-31 | 2023-05-25 | ClinicalTrials.gov |
| NCT04420260 | Primary Prevention of Infection by COVID-19 in Workers | Na | COVID | Completed | 2021-03-18 | 2021-07-05 | ClinicalTrials.gov |
| NCT05963646 | Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patient… | — | Age-Related Macular Degeneration | Completed | 2021-03-16 | 2023-12-31 | ClinicalTrials.gov |
| NCT07531329 | Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Canc… | — | Treatment-naive Prostate Cancer | Recruiting | 2021-03-05 | 2028-03-05 | ClinicalTrials.gov |
| NCT03749850 | Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-r… | Phase1 | Metastatic Breast Cancer | Unknown | 2021-03-01 | 2022-11-01 | ClinicalTrials.gov |
| NCT04698161 | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncolog… | — | Non Small Cell Lung Cancer | Completed | 2021-02-25 | 2022-07-11 | ClinicalTrials.gov |
| NCT04698148 | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastroi… | — | Clostridium Difficile Infection | Completed | 2021-02-08 | 2022-05-10 | ClinicalTrials.gov |
| NCT04859322 | The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino … | Na | Non-Alcoholic Fatty Liver Disease | Completed | 2021-02-08 | 2021-12-09 | ClinicalTrials.gov |
| NCT04689074 | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney … | — | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Completed | 2021-02-03 | 2022-05-10 | ClinicalTrials.gov |
| NCT04763369 | Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of… | Phase2 | Retinitis Pigmentosa (RP) | Unknown | 2021-02-01 | 2022-06-01 | ClinicalTrials.gov |
| NCT04873414 | Convalescent Plasma as Adjunct Therapy for COVID-19 | Phase2 | COVID-19 | Unknown | 2020-12-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT05610878 | Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting | Phase1 | Romberg Disease | Recruiting | 2020-11-20 | 2025-12-01 | ClinicalTrials.gov |
| NCT05610865 | Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foo… | Phase1 | Diabetic Foot Ulcer | Recruiting | 2020-11-20 | 2025-12-01 | ClinicalTrials.gov |
| NCT04870164 | Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potenti… | Phase1 | COVID-19 | Terminated | 2020-11-18 | 2022-01-06 | ClinicalTrials.gov |
| NCT04715750 | Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patient… | Phase1 | Alzheimer Disease | Completed | 2020-11-12 | 2022-10-26 | ClinicalTrials.gov |
| NCT04625595 | Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabe… | Phase1 | Type1 Diabetes | Completed | 2020-11-09 | 2021-07-31 | ClinicalTrials.gov |
| NCT05101382 | A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (AL… | — | Colorectal Cancer | Recruiting | 2020-10-28 | 2026-12-01 | ClinicalTrials.gov |
| NCT04519749 | An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Dise… | Phase1 | Fabry Disease | Active_Not_Recruiting | 2020-09-01 | 2030-06-01 | ClinicalTrials.gov |
| NCT04625023 | A Master Protocol Empowering Mechanobiology Translation Research in Breast Canc… | — | Breast Cancer | Recruiting | 2020-07-16 | 2026-12-01 | ClinicalTrials.gov |
| NCT04259944 | Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage I… | Phase2 | Colon Cancer | Unknown | 2020-06-16 | 2024-10-15 | ClinicalTrials.gov |
| NCT04517149 | 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) | Phase1 | X-Linked Retinitis Pigmentosa | Active_Not_Recruiting | 2020-06-09 | 2029-05-01 | ClinicalTrials.gov |
| NCT04483440 | Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia | Phase1 | Choroideremia | Active_Not_Recruiting | 2020-06-02 | 2027-08-31 | ClinicalTrials.gov |
| NCT04248998 | Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer | Phase2 | Triple-negative Breast Cancer | Unknown | 2020-05-05 | 2024-05-01 | ClinicalTrials.gov |
| NCT04407208 | Convalescent Plasma Therapy in Patients With COVID-19 | Phase1 | Convalescence | Completed | 2020-05-01 | 2020-06-22 | ClinicalTrials.gov |
| NCT05046769 | COVID-19: A Scope Research on Epidemiology and Clinical Course | — | Covid19 | Unknown | 2020-04-28 | 2025-12-31 | ClinicalTrials.gov |
| NCT04341168 | Clinical and Immunological Characterisation of COVID-19 in Children, Adolescent… | — | COVID-19 | Unknown | 2020-04-01 | 2020-10-01 | ClinicalTrials.gov |
| NCT04425590 | The Benefit of Add On DLBS1033 for Ischemic Stroke Patient | Phase2 | Ischemic Stroke | Unknown | 2020-04-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT04140097 | Predictors of Acute Exacerbation in Patients With COPD - an Observational Study | — | Chronic Obstructive Pulmonary Disease | Active_Not_Recruiting | 2020-02-26 | 2026-04-30 | ClinicalTrials.gov |
| NCT04017130 | A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma | Phase1 | Relapsed and/or Refractory Multiple Myeloma | Terminated | 2020-02-05 | 2023-12-13 | ClinicalTrials.gov |
| NCT06501521 | Non-invasive Brain Tumor Molecular Diagnostics and Monitoring | — | Brain Tumor | Recruiting | 2020-01-01 | 2030-12-31 | ClinicalTrials.gov |
| NCT04029922 | Study of MT-5111 in HER2-positive Solid Tumors | Phase1 | HER2-positive Solid Cancers | Terminated | 2019-11-12 | 2023-04-27 | ClinicalTrials.gov |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET… | Early_Phase1 | Breast Carcinoma | Active_Not_Recruiting | 2019-11-05 | 2031-10-17 | ClinicalTrials.gov |
| NCT04073875 | 18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis | — | Thrombosis Cardiac | Completed | 2019-10-22 | 2021-10-13 | ClinicalTrials.gov |
| NCT04120935 | ALFAOMEGA Master Observational Trial | — | Colorectal Cancer | Recruiting | 2019-10-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT04226313 | Self-sampling for Non-attenders to Cervical Cancer Screening | Na | Cervical Cancer | Recruiting | 2019-09-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT04049903 | Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patient… | Phase1 | Advanced Solid Tumor | Completed | 2019-09-02 | 2022-12-21 | ClinicalTrials.gov |
| NCT04110925 | Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CV… | Na | MDS | Unknown | 2019-09-01 | 2021-09-01 | ClinicalTrials.gov |
| NCT04193332 | Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery | Na | Hypoparathyroidism Postprocedural | Unknown | 2019-08-16 | 2023-12-01 | ClinicalTrials.gov |
| NCT04131543 | Phase II Study With Cabozantinib in Patients With RET Positive NSCLC | Phase2 | Non Small Cell Lung Cancer | Unknown | 2019-08-07 | 2022-08-07 | ClinicalTrials.gov |
| NCT04019808 | Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population | — | Gastric Cancer | Completed | 2019-07-30 | 2023-12-31 | ClinicalTrials.gov |
| NCT03970850 | NeuMoDx PrEDiCTiNG Study Evaluation Plan | Na | Chlamydia Trachomatis Infection | Completed | 2019-07-22 | 2020-02-25 | ClinicalTrials.gov |
| NCT04037150 | Circulating DNA in Surgically Treated NSCLC | — | Non-small Cell Lung Cancer | Unknown | 2019-07-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT04015466 | Advanced GC Multi-omic Characterization in EU and CELAC Populations | — | Gastric Cancer | Completed | 2019-06-12 | 2023-12-31 | ClinicalTrials.gov |
| NCT03957031 | Gastric Cancer Risk Factors Associated With EU and CELAC Populations | — | Cancer, Gastric | Completed | 2019-05-31 | 2023-12-31 | ClinicalTrials.gov |
| NCT03976518 | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHAN… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2019-05-07 | 2024-02-12 | ClinicalTrials.gov |
| NCT03645395 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Re… | Phase2 | Non-hodgkin Lymphoma | Terminated | 2019-04-08 | 2021-03-10 | ClinicalTrials.gov |
| NCT04538521 | NiaMIT Continuation With Early-stage Mitochondrial Myopathy Patients | Na | Mitochondrial Myopathies | Completed | 2019-02-11 | 2020-09-18 | ClinicalTrials.gov |
| NCT03795688 | The Role of Sex Steroids and Serotonin Brain Dynamics in Perinatal Mental Health | — | Major Depressive Disorder | Completed | 2019-01-24 | 2020-12-01 | ClinicalTrials.gov |
| NCT03519412 | Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically … | Phase2 | Colorectal Neoplasms | Completed | 2019-01-23 | 2025-01-08 | ClinicalTrials.gov |
| NCT03700411 | Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Can… | Phase4 | Colorectal Cancer | Completed | 2019-01-07 | 2023-12-06 | ClinicalTrials.gov |
| NCT03700541 | Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colore… | Phase4 | Colorectal Cancer | Completed | 2019-01-07 | 2023-12-06 | ClinicalTrials.gov |
| NCT03886090 | Facilitating Motor Skill Learning in Parkinson's Disease II (FaST-PD II) | Na | Parkinson Disease | Completed | 2019-01-01 | 2020-02-24 | ClinicalTrials.gov |
| NCT03811587 | Clinical Feasibility and Efficacy of Intermittent Use of a Fasting Mimicking Di… | Na | Diabetes Mellitus, Type 2 | Completed | 2018-11-05 | 2021-08-06 | ClinicalTrials.gov |
| NCT04427163 | Assesment of Multiomics Profiles in Health and Disease. | — | Genetic Predisposition to Disease | Recruiting | 2018-09-01 | 2029-03-30 | ClinicalTrials.gov |
| NCT04133610 | HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs… | Na | Cervical Cancer | Completed | 2018-09-01 | 2019-11-25 | ClinicalTrials.gov |
| NCT03488251 | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcita… | Phase2 | Non-hodgkin Lymphoma,B Cell | Terminated | 2018-08-20 | 2021-03-12 | ClinicalTrials.gov |
| NCT03620409 | Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- … | — | Sepsis | Completed | 2018-05-09 | 2022-06-15 | ClinicalTrials.gov |
| NCT04012385 | Effects of Lifestyle Changes on Semen Quality in Healthy Young Men Living in Hi… | Na | Fertility Disorders | Completed | 2018-05-02 | 2019-11-06 | ClinicalTrials.gov |
| NCT04619524 | Biomarkers of Endometrial Receptivity | Na | IVF | Recruiting | 2018-05-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT03589014 | Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation | Phase2 | Cerebral Cavernous Malformation | Completed | 2018-04-11 | 2021-12-31 | ClinicalTrials.gov |
| NCT03418532 | MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC | Phase1 | EGFR-mutated NSCLC (Disorder) | Terminated | 2018-03-22 | 2020-04-24 | ClinicalTrials.gov |
| NCT03455179 | Effects of Slow-speed Traditional Resistance Training, High-speed Resistance Tr… | Na | Aging | Completed | 2018-03-05 | 2018-07-31 | ClinicalTrials.gov |
| NCT03829176 | Investigating the Feasibility and Implementation of Whole Genome Sequencing in … | Na | Hereditary Disease | Completed | 2018-03-01 | 2020-10-01 | ClinicalTrials.gov |
| NCT03360461 | EMI-137 in Laparoscopic Colonic Resections | Phase2 | Colonic Cancer | Completed | 2018-02-14 | 2020-03-14 | ClinicalTrials.gov |
| NCT03650127 | Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi Fin… | — | Coronary Heart Disease | Unknown | 2018-02-02 | 2023-12-31 | ClinicalTrials.gov |
| NCT03838237 | Effect of Migalastat on Cardiac Involvement in Fabry Disease | — | Fabry Disease | Completed | 2018-01-10 | 2021-01-22 | ClinicalTrials.gov |
| NCT04026815 | Health Status and Its Socio-economic Covariates of the Older Population in Pola… | — | Aging Disorder | Unknown | 2018-01-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT03898505 | Clinical Investigation on the Safety of Avocado Pulp Lipids | Early_Phase1 | Obesity | Completed | 2017-11-24 | 2018-08-01 | ClinicalTrials.gov |
| NCT03334552 | Identification of Broadly HIV-1 Neutralizing Antibodies (bNAb) in HIV-infected … | — | HIV/AIDS | Unknown | 2017-10-15 | 2024-08-01 | ClinicalTrials.gov |
| NCT02920203 | Genetic Autopsy and Sudden Death | — | Sudden Death | Unknown | 2017-10-11 | 2020-12-01 | ClinicalTrials.gov |
| NCT03323346 | Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer | Phase2 | Breast Neoplasm Female | Recruiting | 2017-09-29 | 2025-12-31 | ClinicalTrials.gov |
| NCT03084926 | First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274… | Phase1 | Neoplasms | Completed | 2017-08-08 | 2021-12-13 | ClinicalTrials.gov |
| NCT04006886 | Gluten-free Diet in Patients With Primary Sclerosing Cholangitis (PSC) | Na | Reduction of Intestinal Inflammatory Activity | Completed | 2017-07-11 | 2019-07-01 | ClinicalTrials.gov |
| NCT03123575 | Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Pa… | — | HIV | Unknown | 2017-06-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Mult… | Phase1 | Multiple Myeloma in Relapse | Completed | 2017-05-23 | 2021-01-13 | ClinicalTrials.gov |
| NCT03142724 | Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects | Phase1 | Healthy Volunteers | Completed | 2017-05-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT03082768 | Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects | Early_Phase1 | Healthy Volunteers | Completed | 2017-03-03 | 2018-03-01 | ClinicalTrials.gov |
| NCT03245216 | Facilitating Motor Skill Learning in Parkinson's Disease | Na | Parkinson Disease | Completed | 2017-03-01 | 2018-09-30 | ClinicalTrials.gov |
| NCT03094546 | Polyamine-enriched Diet in Elderly Individuals With Subjective Cognitive Decline | Phase2 | Subjective Cognitive Decline (SCD) | Completed | 2017-01-01 | 2020-10-01 | ClinicalTrials.gov |
| NCT03121885 | Human Metabolic Dynamics at Rest and During Aerobic Exercise Under Normobaric N… | Na | Energy Metabolism | Completed | 2017-01-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT02994368 | "Natural History" Study of Choroideremia | — | Choroideremia | Terminated | 2016-12-01 | 2021-10-01 | ClinicalTrials.gov |
| NCT03058965 | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging T… | Early_Phase1 | Alzheimer Disease | Completed | 2016-11-29 | 2018-05-11 | ClinicalTrials.gov |
| NCT02954588 | Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensiti… | Na | Abdominal Obesity Metabolic Syndrome | Completed | 2016-10-14 | 2020-08-08 | ClinicalTrials.gov |
| NCT02934009 | Dermal Profile Analysis Using the NMR-MOUSE | Na | Exposure to Magnetic Field | Terminated | 2016-10-01 | 2020-05-08 | ClinicalTrials.gov |
| NCT02869035 | Treatment Outcome in Major Depressive Disorder | Phase1 | Major Depressive Disorder | Completed | 2016-08-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT03080051 | Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Prote… | Early_Phase1 | Progressive Supranuclear Palsy | Completed | 2016-08-01 | 2017-03-06 | ClinicalTrials.gov |
| NCT02743741 | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Posi… | Na | Neuroendocrine Tumors | Active_Not_Recruiting | 2016-07-15 | 2026-06-01 | ClinicalTrials.gov |
| NCT02862262 | A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic P… | Na | Bordetella Infections | Completed | 2016-07-01 | 2016-11-14 | ClinicalTrials.gov |
| NCT03876002 | Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodia… | Phase1 | Healthy Volunteers | Completed | 2016-06-28 | 2018-02-07 | ClinicalTrials.gov |
| NCT02755246 | Polyamine-enriched Diet in Healthy Older Adults With Subjective Cognitive Decli… | Phase2 | Subjective Cognitive Decline | Completed | 2016-04-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02615067 | Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low… | Phase3 | Prostate Cancer | Completed | 2015-12-01 | 2017-12-28 | ClinicalTrials.gov |
| NCT02556346 | Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple … | Phase1 | Chronic B-cell Lymphocytic Leukemia | Withdrawn | 2015-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT04110678 | Tolerance to NeuroEPO in Parkinson Disease | Phase1 | Parkinson Disease | Completed | 2015-11-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02519582 | Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Pat… | Phase2 | Colorectal Cancer | Unknown | 2015-08-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT02444598 | Trial of Negative-pressure Wound Therapy Use in Conflict-related Extremity Woun… | Na | Wounds, Gunshot | Completed | 2015-06-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT04157361 | Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthm… | — | Bronchial Asthma | Recruiting | 2015-05-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT02531360 | Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Prote… | Early_Phase1 | Alzheimer's Disease (AD) | Completed | 2015-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02353494 | Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment o… | — | Plasmodium Falciparum Infection | Completed | 2015-03-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02385019 | A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Gr… | Phase1 | Graft vs Host Disease | Unknown | 2015-03-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or… | Phase1 | Non-Hodgkin's B-cell Lymphoma | Terminated | 2015-02-01 | 2021-03-22 | ClinicalTrials.gov |
| NCT02370524 | Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging… | Phase1 | Alzheimer's Disease (AD) | Completed | 2015-01-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01787227 | A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen P… | — | Respiratory Tract Infection | Completed | 2015-01-01 | — | ClinicalTrials.gov |
| NCT02314871 | Effects of Different Types of Perioperative Analgesia on Minimal Residual Disea… | Phase4 | Colon Cancer | Completed | 2015-01-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02370563 | PET Imaging of Intracranial Cancers With 18F-FSPG | Phase1 | Brain Cancer | Terminated | 2014-11-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02260817 | Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer | Phase3 | Metastatic Prostate Cancer | Completed | 2014-10-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT03388723 | Intergenerational Programming of Diabesity in Offspring of Women With Gestation… | — | Gestational Diabetes | Completed | 2014-09-02 | 2018-11-30 | ClinicalTrials.gov |
| NCT02333175 | Care for Late Stage Parkinsonism | Na | Parkinson's Disease | Completed | 2014-09-01 | 2019-03-31 | ClinicalTrials.gov |
| NCT02243683 | Safety Study of Immune System Modulator for Autoimmune Diseases | Phase1 | Healthy Volunteers | Completed | 2014-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02239172 | PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine | Phase1 | Anthrax | Completed | 2014-08-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02065713 | Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monothe… | Phase3 | Psoriatic Arthritis | Completed | 2014-08-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02214563 | Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hem… | Phase4 | Kidney Failure, Chronic | Completed | 2014-08-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02001428 | Malaria in Early Life Study | Na | Plasmodium Falciparum Malaria | Completed | 2014-07-21 | 2017-05-17 | ClinicalTrials.gov |
| NCT02194426 | First-in-human Study to Investigate the Safety, Tolerability and Blood Levels o… | Phase1 | Neoplasms | Completed | 2014-07-01 | 2018-02-20 | ClinicalTrials.gov |
| NCT03973203 | Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients | Na | Mitochondrial Myopathies | Completed | 2014-06-01 | 2018-12-31 | ClinicalTrials.gov |
| NCT01961934 | C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necr… | Phase2 | Gliomas | Withdrawn | 2014-05-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT06618469 | Effects of Resistance Training Programes At Different Intensities on Musculoske… | Na | Aging | Completed | 2014-05-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02280538 | Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra… | Na | Osteoarthritis Of Knee | Unknown | 2014-04-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02103894 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Ta… | Phase1 | Alzheimer's Disease (AD) | Completed | 2014-02-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02067286 | Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Li… | — | Influenza A | Completed | 2014-01-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02487576 | The CLOCK Study - A Human Dietary Intervention Study on Peripheral Circadian Cl… | Na | Metabolic Response to Dietary Modification | Completed | 2014-01-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02753192 | Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison | Na | Parkinson's Disease | Unknown | 2014-01-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02068469 | In Vitro Diagnostic Device for the Detection of Strep A | — | Streptococcal Sore Throat | Completed | 2013-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02013687 | Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission… | Phase1 | Malaria | Completed | 2013-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01905826 | Natural History Study of GATA2 Deficiency and Related Disorders | — | GATA2 Deficiency | Recruiting | 2013-08-26 | — | ClinicalTrials.gov |
| NCT01856244 | Stability and Balance in Locomotion Through Exercise | Phase1 | Parkinson's Disease | Completed | 2013-06-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02017340 | A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease | Phase3 | Alzheimer's Disease | Completed | 2013-04-24 | 2016-12-16 | ClinicalTrials.gov |
| NCT01583842 | 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for… | Early_Phase1 | Neuroblastoma | Terminated | 2013-04-09 | 2021-02-25 | ClinicalTrials.gov |
| NCT01859767 | Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyl… | Phase1 | Alzheimer's Disease | Completed | 2013-04-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02092896 | Liraglutide as add-on to Insulin in Type 1 Diabetes | Phase3 | Diabetes | Completed | 2013-03-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01506427 | A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients | Phase1 | Head and Neck Cancer | Withdrawn | 2012-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01667536 | A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPL… | Phase2 | Prostate Cancer | Completed | 2012-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01654874 | 99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess th… | Phase1 | Prostate Cancer | Completed | 2012-07-01 | — | ClinicalTrials.gov |
| NCT01291264 | Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria G… | — | Chlamydia Infection | Terminated | 2012-06-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01602471 | [F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid A… | Phase2 | Carotid Stenosis | Terminated | 2012-05-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01615406 | A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men Wi… | Phase1 | Prostate Cancer | Completed | 2012-04-01 | — | ClinicalTrials.gov |
| NCT01530269 | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-hig… | Phase2 | Prostate Cancer | Completed | 2012-04-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT01519908 | Markers and Response to Cardiac Resynchronization Therapy | — | Heart Failure | Completed | 2012-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01417455 | Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing S… | — | Rheumatoid Arthritis | Completed | 2012-01-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01572701 | Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Unde… | Phase1 | Prostate Cancer | Completed | 2012-01-01 | — | ClinicalTrials.gov |
| NCT01408602 | A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patie… | Phase2 | Rheumatoid Arthritis | Unknown | 2011-11-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01447901 | Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in… | — | Hyperlipoproteinemia Type I | Terminated | 2011-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01709045 | ParisK: Correlation of Imaging Techniques With Histology | — | Stroke | Completed | 2011-08-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01326013 | A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathog… | — | Infectious | Completed | 2011-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01465165 | Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Ab… | — | Major Depressive Disorder | Terminated | 2011-05-15 | 2012-06-24 | ClinicalTrials.gov |
| NCT01297088 | PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With… | Phase1 | Diagnostic Imaging | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01317498 | The VMVN Study: Virological Monitoring in Viet Nam | Na | HIV Infection | Completed | 2011-04-01 | 2018-06-30 | ClinicalTrials.gov |
| NCT01304485 | PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate … | Phase2 | Prostate Cancer | Completed | 2011-04-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT01279785 | A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Cam… | — | Prostate Cancer | Withdrawn | 2011-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01145170 | Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma | Phase2 | Diffuse Intrinsic Brainstem Gliomas | Completed | 2011-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01287845 | PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety an… | Phase1 | Diagnostic Imaging | Completed | 2011-02-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT02661789 | Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy… | Na | Postpartum Depression | Completed | 2011-01-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01186601 | Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer | Phase1 | Neoplasms | Completed | 2010-12-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01261754 | A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prosta… | Phase1 | Prostate Cancer | Completed | 2010-12-01 | — | ClinicalTrials.gov |
| NCT01205321 | PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistributio… | Phase1 | Diagnostic Imaging | Completed | 2010-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01448577 | Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence … | — | Lipoprotein Lipase Deficiency | Unknown | 2010-11-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01250795 | Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults | Phase1 | Healthy | Completed | 2010-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01452113 | Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) T… | Phase2 | Diabetes Mellitus | Completed | 2010-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01177202 | Study of the Safety and Immunogenicity of H1N1 Vaccine | Phase1 | H1N1 Flu | Completed | 2010-09-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01217021 | Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558 | Early_Phase1 | Alzheimer Disease | Completed | 2010-09-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01103310 | Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and … | Phase1 | Diagnostic Imaging | Completed | 2010-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00943059 | Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeleta… | Na | Diabetes Mellitus, Type 2 | Completed | 2010-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01086761 | Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular… | Phase1 | Wet Age-Related Macular Degeneration | Terminated | 2010-03-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01075399 | Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypox… | Phase2 | Head and Neck Cancer | Completed | 2010-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01042678 | Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema | Phase1 | Diabetic Macular Edema | Terminated | 2010-02-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00992173 | Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | Phase2 | Neuroblastoma | Withdrawn | 2010-01-01 | — | ClinicalTrials.gov |
| NCT01240161 | Personalized Translational Platform for Biomarker Discovery in Brain Tumors | — | High Grade Glioma | Completed | 2009-12-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT00747825 | Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melano… | Phase1 | Metastatic Melanoma | Terminated | 2009-12-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01020838 | Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion… | Phase3 | Alzheimer Disease | Completed | 2009-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01730417 | Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrac… | Phase1 | Neuroendocrine Tumors | Completed | 2009-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00992745 | A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide i… | Phase1 | Prostate Cancer | Completed | 2009-10-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01005030 | Spectroscopy in Parkinson Disease | — | Parkinson Disease | Unknown | 2009-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00988936 | Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to … | Phase2 | Metastatic Breast Cancer | Completed | 2009-09-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00927108 | Rajavtihi Neuronal Adult Stem Cells Project | Phase2 | Alzheimer's Disease | Withdrawn | 2009-07-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00874614 | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relaps… | Phase2 | Pheochromocytoma | Unknown | 2009-06-04 | 2021-02-01 | ClinicalTrials.gov |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | Phase2 | Neuroblastoma | Withdrawn | 2009-06-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01018927 | Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Dise… | — | Multiple Myeloma | Terminated | 2009-06-01 | 2017-05-30 | ClinicalTrials.gov |
| NCT00918281 | Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intra… | Phase2 | Solid Tumors | Completed | 2009-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00928304 | Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion … | Phase2 | Down Syndrome | Completed | 2009-06-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01054716 | Evaluation of a Noninvasive Fetal RHD Genotyping Test | — | Rhesus D Genotype | Completed | 2009-05-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00911729 | Content Validation of Quality of Life and Symptom Questionnaires for Pheochromo… | — | Pheochromocytoma | Terminated | 2009-04-01 | — | ClinicalTrials.gov |
| NCT00884520 | An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037 | Early_Phase1 | Lung Cancer | Completed | 2009-04-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00891306 | Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Ad… | Phase2 | Familial Lipoprotein Lipase Deficiency | Completed | 2009-02-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00847509 | A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Pa… | Na | Lung Cancer | Completed | 2009-02-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT05619562 | Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Pat… | — | Non Small Cell Lung Cancer | Completed | 2009-01-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT00895323 | Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer | Phase1 | Colorectal Cancer | Unknown | 2008-11-01 | — | ClinicalTrials.gov |
| NCT00614354 | Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patien… | Phase2 | Acute Coronary Syndrome | Completed | 2008-10-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00683761 | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | Phase1 | Malignant Glioma | Unknown | 2008-08-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01010802 | Safety Study of Erythropoietin (EPO) in Parkinson's Disease | Phase1 | Parkinson Disease | Completed | 2008-08-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00750282 | Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion… | Phase2 | Alzheimer Disease | Completed | 2008-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00743353 | Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent,… | Early_Phase1 | Sarcoma | Completed | 2008-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00720993 | Colorectal Cancer Screening Validation Study | — | Colorectal Cancer Screening | Unknown | 2008-08-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01140152 | Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysf… | — | Intestinal Transplant | Completed | 2008-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT01138111 | Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mil… | Phase1 | Alzheimer Disease | Completed | 2008-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00696930 | Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Sympto… | Phase2 | Malignant Carcinoid Tumor | Withdrawn | 2008-06-01 | — | ClinicalTrials.gov |
| NCT00659984 | N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory Hig… | Phase2 | Neuroblastoma | Completed | 2008-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00760292 | Genetic Variants and Phenotypic Characteristics of Patients With T2DM | — | Type 2 Diabetes Mellitus | Unknown | 2008-05-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00712829 | Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism… | Phase1 | Prostate Cancer | Completed | 2008-05-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00657813 | Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Depo… | Phase1 | Alzheimer Disease | Terminated | 2008-03-01 | 2008-09-30 | ClinicalTrials.gov |
| NCT00591058 | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glio… | Phase1 | Malignant Glioma | Unknown | 2008-02-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00606424 | An Exploratory, Open Label, Single Center Study of [F-18]HX4 | Early_Phase1 | Head and Neck Cancer | Completed | 2008-01-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00595738 | Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output a… | — | Congestive Heart Failure | Completed | 2007-12-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00553748 | Phase I, Open Label, Single Center Safety Study of [F-18]FLT | Phase1 | Brain Cancer | Completed | 2007-11-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00544453 | Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Depo… | Phase1 | Alzheimer Disease | Terminated | 2007-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT01109498 | Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated V… | Phase2 | Familial Lipoprotein Lipase Deficiency | Unknown | 2007-08-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00514501 | Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Sy… | Phase2 | Acute Coronary Syndrome | Completed | 2007-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromoc… | Phase1 | Pheochromocytoma | Completed | 2007-04-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00456417 | Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in C… | Phase1 | Alzheimers Disease | Completed | 2007-04-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00448799 | Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Compa… | Phase1 | Alzheimers Disease | Completed | 2007-03-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00439010 | Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subj… | Phase1 | Alzheimers Disease | Completed | 2007-02-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00427674 | Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects… | Phase1 | Parkinson Disease | Terminated | 2007-01-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00387075 | A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease | Phase2 | Parkinson Disease | Unknown | 2006-11-01 | 2023-08-01 | ClinicalTrials.gov |
| NCT00397228 | ALTROPANE® SPECT Imaging in Patients With Parkinson Disease | Phase2 | Parkinson Disease | Completed | 2006-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00379132 | 131-I-TM-601 Study in Adults With Solid Tumors | Phase1 | Breast Cancer | Completed | 2006-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT03303833 | The GEOLynch Cohort Study | — | Lynch Syndrome | Recruiting | 2006-07-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT00348426 | Botulism Outbreak in Thailand (Episode II) | — | Botulism | Completed | 2006-06-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00339131 | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraga… | Phase1 | Pheochromocytoma | Completed | 2006-06-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00316797 | Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects | Phase1 | Neurodegenerative Diseases | Completed | 2006-04-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00314080 | Treatment of Survivors After Botulism Outbreak | — | Respiratory Failure | Completed | 2006-03-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00287248 | Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain | Phase1 | Alzheimer Disease | Completed | 2006-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00315250 | Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Di… | Phase2 | Parkinson's Disease | Completed | 2006-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00273351 | Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression … | Phase2 | Parkinson Disease | Completed | 2006-01-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00367731 | NOW Thai HAART Study | — | HIV | Completed | 2005-01-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00114309 | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | Phase2 | Malignant Glioma | Unknown | 2004-11-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00200447 | An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) | Phase2 | Parkinson's Disease | Completed | 2004-03-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT03337347 | Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorect… | Na | Colorectal Cancer | Completed | 2004-01-01 | 2015-10-23 | ClinicalTrials.gov |
| NCT00117195 | A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease | — | Parkinson's Disease | Completed | 2003-05-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00129675 | Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic … | Phase2 | Parkinsonian Syndrome | Completed | 2003-02-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00040573 | Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recur… | Phase1 | Glioma | Completed | 2002-06-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00339963 | Genome Expression in Lymphoma, Leukemia and Multiple Myeloma | — | Leukemia | Completed | 2001-11-09 | — | ClinicalTrials.gov |
| NCT00006458 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or … | Phase1 | Lung Cancer | Unknown | 2000-08-01 | — | ClinicalTrials.gov |
| NCT00006347 | Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Sm… | Phase1 | Lung Cancer | Unknown | 2000-08-01 | — | ClinicalTrials.gov |
| NCT00005939 | Brachytherapy in Treating Patients With Recurrent Prostate Cancer | Phase1 | Prostate Cancer | Unknown | 1999-11-01 | — | ClinicalTrials.gov |
| NCT00004129 | Phosphorus 32 in Treating Patients With Glioblastoma Multiforme | Phase1 | Brain and Central Nervous System Tumors | Unknown | 1999-09-01 | — | ClinicalTrials.gov |
| NCT00004048 | Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Trans… | Phase1 | Head and Neck Cancer | Completed | 1998-09-01 | 2002-05-01 | ClinicalTrials.gov |
| NCT00004085 | Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patien… | Phase1 | Breast Cancer | Completed | 1998-05-01 | — | ClinicalTrials.gov |
| NCT00004084 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or … | Phase1 | Leukemia | Completed | 1998-04-01 | — | ClinicalTrials.gov |
| NCT00004086 | Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem… | Phase1 | Leukemia | Unknown | 1997-06-01 | — | ClinicalTrials.gov |
| NCT00004087 | Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantat… | Phase1 | Colorectal Cancer | Completed | 1997-03-01 | — | ClinicalTrials.gov |
| NCT00002689 | Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer | Phase2 | Pancreatic Cancer | Completed | 1995-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00132626 | Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian… | Phase2 | Parkinson's Disease | Completed | 1992-09-01 | 2005-08-01 | ClinicalTrials.gov |
Total clinical trials: 332
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| PROSTest | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| 18F-rhPSMA-7.3 | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | NOT_YET_RECRUITING | NCT07593079 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer Screening | RECRUITING | NCT06741293 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer Screening | RECRUITING | NCT06741293 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer Screening | RECRUITING | NCT06741293 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer Screening | RECRUITING | NCT06741293 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer Screening | RECRUITING | NCT06741293 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer Screening | RECRUITING | NCT06741293 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer Screening | RECRUITING | NCT06741293 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer Screening | RECRUITING | NCT06741293 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer (CRC) | RECRUITING | NCT06734156 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer (CRC) | RECRUITING | NCT06734156 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer (CRC) | RECRUITING | NCT06734156 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer (CRC) | RECRUITING | NCT06734156 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer (CRC) | RECRUITING | NCT06734156 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer (CRC) | RECRUITING | NCT06734156 |
| [123I] AV 39 | Other | Phase PHASE1 | Alzheimers Disease | COMPLETED | NCT00439010 |
| 131I-TM-601 | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00040573 |
| 131I-TM-601 | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00040573 |
| [123I] IMPY & SPECT Imaging | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT00287248 |
| [18F]T807 ([18F]MNI-777) | Other | Phase PHASE1 | Alzheimer's Disease (AD) | COMPLETED | NCT02103894 |
| [18F]T807 ([18F]MNI-777) | Other | Phase PHASE1 | Alzheimer's Disease (AD) | COMPLETED | NCT02103894 |
| [18F]Florbetapir | Other | Phase EARLY_PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT03080051 |
| [18F]MNI-952 | Other | Phase EARLY_PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT03080051 |
| [18F]Florbetapir | Other | Phase EARLY_PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT03080051 |
| [18F]MNI-952 | Other | Phase EARLY_PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT03080051 |
| [18F]MNI-968 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03142724 |
| Niclosamide | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT02519582 |
| DaTscan | Other | Phase EARLY_PHASE1 | Alzheimer Disease | COMPLETED | NCT03058965 |
| [18F]Florbetapir | Other | Phase EARLY_PHASE1 | Alzheimer Disease | COMPLETED | NCT03058965 |
| [18F]MNI-958 | Other | Phase EARLY_PHASE1 | Alzheimer Disease | COMPLETED | NCT03058965 |
| DaTscan | Other | Phase EARLY_PHASE1 | Alzheimer Disease | COMPLETED | NCT03058965 |
| [18F]Florbetapir | Other | Phase EARLY_PHASE1 | Alzheimer Disease | COMPLETED | NCT03058965 |
| [18F]MNI-958 | Other | Phase EARLY_PHASE1 | Alzheimer Disease | COMPLETED | NCT03058965 |
| Circulating tumor DNA | Other | Preclinical | Non-small Cell Lung Cancer | UNKNOWN | NCT04037150 |
| ensovibep | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04834856 |
| MP0274 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03084926 |
| Fasting Mimicking diet | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT03811587 |
| Fasting Mimicking diet | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT03811587 |
| Device for CTC/DTC detection | Device | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT05619562 |
| Device for CTC/DTC detection | Device | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT05619562 |
| LIAISON NES FLU A/B & COVID-19 | Other | Approved | Influenza A | COMPLETED | NCT05897515 |
| LIAISON NES FLU A/B & COVID-19 | Other | Approved | Influenza A | COMPLETED | NCT05897515 |
| LIAISON NES FLU A/B & COVID-19 | Other | Approved | Influenza A | COMPLETED | NCT05897515 |
| Support Group | Other | Approved | Breast Cancer Female | RECRUITING | NCT05642897 |
| Mind | Other | Approved | Breast Cancer Female | RECRUITING | NCT05642897 |
| 4D-310 | Other | Phase PHASE1 | Fabry Disease | RECRUITING | NCT05629559 |
| 4D-310 | Other | Phase PHASE1 | Fabry Disease | RECRUITING | NCT05629559 |
| [18F]-PI2620 | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT05187546 |
| [18F]-PI2620 | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT05187546 |
| Disulfiram | Other | Phase PHASE2 | Breast Neoplasm Female | RECRUITING | NCT03323346 |
| Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI) | Drug | Preclinical | HIV | COMPLETED | NCT00367731 |
| Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI) | Drug | Preclinical | HIV | COMPLETED | NCT00367731 |
| Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI) | Drug | Preclinical | HIV | COMPLETED | NCT00367731 |
| : Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| neuro-electrophysiologic study, repetitive nerve stimulation | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| Botulinum AntiToxin | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| : Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| neuro-electrophysiologic study, repetitive nerve stimulation | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| Botulinum AntiToxin | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| : Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| neuro-electrophysiologic study, repetitive nerve stimulation | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| Botulinum AntiToxin | Other | Preclinical | Botulism | COMPLETED | NCT00348426 |
| [123I]-IBZM imaging | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00200447 |
| Stalevo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00200447 |
| carbidopa/l-dopa/entacapone | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00200447 |
| carbidopa/l-dopa | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00200447 |
| [123I]-IBZM imaging | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00200447 |
| Stalevo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00200447 |
| carbidopa/l-dopa/entacapone | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00200447 |
| carbidopa/l-dopa | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00200447 |
| [123I] AV 39 | Other | Phase PHASE1 | Alzheimers Disease | COMPLETED | NCT00439010 |
| [123I] AV 39 | Other | Phase PHASE1 | Alzheimers Disease | COMPLETED | NCT00439010 |
| [123-I] AV-83 Injection and Imaging Procedures | Procedure | Phase PHASE1 | Alzheimers Disease | COMPLETED | NCT00448799 |
| [123-I] AV-83 Injection and Imaging Procedures | Procedure | Phase PHASE1 | Alzheimers Disease | COMPLETED | NCT00448799 |
| F-18 FLT | Other | Phase PHASE1 | Brain Cancer | COMPLETED | NCT00553748 |
| F-18 FLT | Other | Phase PHASE1 | Brain Cancer | COMPLETED | NCT00553748 |
| Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| neuro-electrophysiologic study, repetitive nerve stimulation | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| Botulinum AntiToxin | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| neuro-electrophysiologic study, repetitive nerve stimulation | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| Botulinum AntiToxin | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| neuro-electrophysiologic study, repetitive nerve stimulation | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| Botulinum AntiToxin | Other | Preclinical | Respiratory Failure | COMPLETED | NCT00314080 |
| F-18 RGD-K5 | Other | Phase EARLY_PHASE1 | Sarcoma | COMPLETED | NCT00743353 |
| F-18 RGD-K5 | Other | Phase EARLY_PHASE1 | Sarcoma | COMPLETED | NCT00743353 |
| 20 mCi dose for a 50 kg individual of [F-18]HX4 | Other | Phase EARLY_PHASE1 | Head and Neck Cancer | COMPLETED | NCT00606424 |
| 20 mCi dose for a 50 kg individual of [F-18]HX4 | Other | Phase EARLY_PHASE1 | Head and Neck Cancer | COMPLETED | NCT00606424 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT00006458 |
| indium In 111 monoclonal antibody MN-14 | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT00006458 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT00006458 |
| indium In 111 monoclonal antibody MN-14 | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT00006458 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT00006347 |
| indium In 111 monoclonal antibody MN-14 | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT00006347 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT00006347 |
| indium In 111 monoclonal antibody MN-14 | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT00006347 |
| 131-I-TM-601 (chlorotoxin) | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00379132 |
| 131-I-TM-601 (chlorotoxin) | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00379132 |
| 131-I-TM-601 (chlorotoxin) | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00379132 |
| 131I-TM601 | Other | Phase PHASE2 | Malignant Glioma | UNKNOWN | NCT00114309 |
| 131-I-TM-601 | Other | Phase PHASE2 | Malignant Glioma | UNKNOWN | NCT00114309 |
| 131I-TM601 | Other | Phase PHASE2 | Malignant Glioma | UNKNOWN | NCT00114309 |
| 131-I-TM-601 | Other | Phase PHASE2 | Malignant Glioma | UNKNOWN | NCT00114309 |
| 131I-TM601 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT00733798 |
| 131I-TM601 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT00733798 |
| yttrium Y 90 epratuzumab | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| indium In 111 LL2 IgG | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| peripheral blood stem cell transplantation | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| autologous bone marrow transplantation | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| ifosfamide | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| etoposide | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| cytarabine | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| cisplatin | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| filgrastim | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| yttrium Y 90 epratuzumab | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| indium In 111 LL2 IgG | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| peripheral blood stem cell transplantation | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| autologous bone marrow transplantation | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| ifosfamide | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| etoposide | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| cytarabine | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| cisplatin | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| filgrastim | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT00004086 |
| 131I-TM601 | Other | Phase PHASE1 | Malignant Glioma | UNKNOWN | NCT00683761 |
| 131I-TM601 | Other | Phase PHASE1 | Malignant Glioma | UNKNOWN | NCT00683761 |
| 131I-TM601 | Other | Phase PHASE1 | Malignant Glioma | UNKNOWN | NCT00683761 |
| TM-601 | Other | Phase PHASE1 | Malignant Glioma | UNKNOWN | NCT00591058 |
| TM-601 | Other | Phase PHASE1 | Malignant Glioma | UNKNOWN | NCT00591058 |
| [123I] MNI-308 | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT00544453 |
| [123I] MNI-308 | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT00544453 |
| [123I] MNI-308 | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT00544453 |
| Blood draw | Other | Preclinical | Parkinson Disease | UNKNOWN | NCT01005030 |
| [F-18] VM4-037 | Other | Phase EARLY_PHASE1 | Lung Cancer | COMPLETED | NCT00884520 |
| [F-18] VM4-037 | Other | Phase EARLY_PHASE1 | Lung Cancer | COMPLETED | NCT00884520 |
| [123I] mZINT injection and serial dynamic SPECT imaging | Other | Phase PHASE1 | Parkinson Disease | TERMINATED | NCT00427674 |
| [123I] mZINT injection and serial dynamic SPECT imaging | Other | Phase PHASE1 | Parkinson Disease | TERMINATED | NCT00427674 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| indium In 111 monoclonal antibody MN-14 | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| peripheral blood stem cell transplantation | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| autologous bone marrow transplantation | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| filgrastim | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| indium In 111 monoclonal antibody MN-14 | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| peripheral blood stem cell transplantation | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| autologous bone marrow transplantation | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| filgrastim | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00004087 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00004085 |
| peripheral blood stem cell transplantation | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00004085 |
| autologous bone marrow transplantation | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00004085 |
| filgrastim | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00004085 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00004085 |
| peripheral blood stem cell transplantation | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00004085 |
| autologous bone marrow transplantation | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00004085 |
| filgrastim | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00004085 |
| yttrium Y 90 epratuzumab | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00004084 |
| indium In 111 LL2 IgG | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00004084 |
| yttrium Y 90 epratuzumab | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00004084 |
| indium In 111 LL2 IgG | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00004084 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| indium In 111 monoclonal antibody MN-14 | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| peripheral blood stem cell transplantation | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| autologous bone marrow transplantation | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| doxorubicin hydrochloride | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| filgrastim | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| yttrium Y 90 monoclonal antibody MN-14 | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| indium In 111 monoclonal antibody MN-14 | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| peripheral blood stem cell transplantation | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| autologous bone marrow transplantation | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| doxorubicin hydrochloride | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| filgrastim | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT00004048 |
| Standard of care therapy for severe decompensated heart failure | Drug | Preclinical | Congestive Heart Failure | COMPLETED | NCT00595738 |
| Standard of care therapy for severe decompensated heart failure | Drug | Preclinical | Congestive Heart Failure | COMPLETED | NCT00595738 |
| Standard of care therapy for severe decompensated heart failure | Drug | Preclinical | Congestive Heart Failure | COMPLETED | NCT00595738 |
| [18F] MNI-558 | Other | Phase EARLY_PHASE1 | Alzheimer Disease | COMPLETED | NCT01217021 |
| [18F] MNI-558 | Other | Phase EARLY_PHASE1 | Alzheimer Disease | COMPLETED | NCT01217021 |
| methylprednisolone | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| cyclosporine | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| mycophenolate mofetil | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| Alipogene Tiparvovec (AMT-011), Human LPL [S447X] | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| methylprednisolone | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| cyclosporine | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| mycophenolate mofetil | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| Alipogene Tiparvovec (AMT-011), Human LPL [S447X] | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| methylprednisolone | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| cyclosporine | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| mycophenolate mofetil | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| Alipogene Tiparvovec (AMT-011), Human LPL [S447X] | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| cyclosporine | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Mycophenolate mofetil | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Alipogene Tiparvovec (AMT-011), Human LPL [S447X] | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| cyclosporine | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Mycophenolate mofetil | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Alipogene Tiparvovec (AMT-011), Human LPL [S447X] | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| cyclosporine | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Mycophenolate mofetil | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Alipogene Tiparvovec (AMT-011), Human LPL [S447X] | Other | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| 111-In capromab pendetide | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00992745 |
| 123-I-MIP-1072 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00992745 |
| 111-In capromab pendetide | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00992745 |
| 123-I-MIP-1072 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00992745 |
| 111-In capromab pendetide | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00992745 |
| 123-I-MIP-1072 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00992745 |
| 131-I-MIP-1145 | Other | Phase PHASE1 | Metastatic Melanoma | TERMINATED | NCT00747825 |
| 123-I-MIP-1095 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00712829 |
| 123-I-MIP-1072 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00712829 |
| Ultratrace iobenguane I 131 | Other | Phase PHASE1 | Pheochromocytoma | COMPLETED | NCT00339131 |
| Ultratrace iobenguane I 131 | Other | Phase PHASE1 | Pheochromocytoma | COMPLETED | NCT00339131 |
| Automated Neuropsychological Assessment Matrix | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00117195 |
| Automated Neuropsychological Assessment Matrix | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00117195 |
| Automated Neuropsychological Assessment Matrix | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00117195 |
| [F-18]RGD-K5 | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT00988936 |
| [F-18]RGD-K5 | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT00988936 |
| no carrier added metaiodobenzylguanidine | Other | Phase PHASE1 | Neuroendocrine Tumors | COMPLETED | NCT01730417 |
| no carrier added metaiodobenzylguanidine | Other | Phase PHASE1 | Neuroendocrine Tumors | COMPLETED | NCT01730417 |
| [F-18] HX4 | Other | Phase PHASE1 | Head and Neck Cancer | WITHDRAWN | NCT01506427 |
| [F-18] HX4 | Other | Phase PHASE1 | Head and Neck Cancer | WITHDRAWN | NCT01506427 |
| [F-18] HX4 | Other | Phase PHASE1 | Head and Neck Cancer | WITHDRAWN | NCT01506427 |
| BAY86-9596 | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01297088 |
| BAY86-9596 | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01297088 |
| BAY1075553 | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01287845 |
| BAY1075553 | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01287845 |
| BAY1075553 | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01287845 |
| Bombesin (68Ga) labeled (BAY86-7548) | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01205321 |
| Bombesin (68Ga) labeled (BAY86-7548) | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01205321 |
| Cellulosum Mycrocryst | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT00943059 |
| Acipimox | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT00943059 |
| Cellulosum Mycrocryst | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT00943059 |
| Acipimox | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT00943059 |
| [F 18]HX4 | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01075399 |
| [F 18]HX4 | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01075399 |
| iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2 | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| whole-body scintigraphy | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| pharmacological study | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| enzyme-linked immunosorbent assay | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2 | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| whole-body scintigraphy | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| pharmacological study | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| enzyme-linked immunosorbent assay | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2 | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| whole-body scintigraphy | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| pharmacological study | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| enzyme-linked immunosorbent assay | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT00895323 |
| [F-18]RDG-K5 | Other | Phase PHASE2 | Carotid Stenosis | TERMINATED | NCT01602471 |
| [F-18]RDG-K5 | Other | Phase PHASE2 | Carotid Stenosis | TERMINATED | NCT01602471 |
| [F-18]FLT | Other | Approved | Lung Cancer | COMPLETED | NCT00847509 |
| [F-18]FLT | Other | Approved | Lung Cancer | COMPLETED | NCT00847509 |
| [F-18]FLT | Other | Approved | Lung Cancer | COMPLETED | NCT00847509 |
| 99mTc-glucarate solution | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00614354 |
| 99mTc-glucarate solution | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00614354 |
| 99mTc-glucarate solution | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00614354 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE2 | Down Syndrome | COMPLETED | NCT00928304 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE2 | Down Syndrome | COMPLETED | NCT00928304 |
| [123I] IMPY & SPECT Imaging | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT00287248 |
| Vildagliptin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01452113 |
| 123-I INER | Other | Phase PHASE1 | Neurodegenerative Diseases | COMPLETED | NCT00316797 |
| 123-I INER | Other | Phase PHASE1 | Neurodegenerative Diseases | COMPLETED | NCT00316797 |
| [123I]β-CIT | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00315250 |
| [123I]β-CIT | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00315250 |
| [123I]B-CIT | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00273351 |
| [123I]B-CIT | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00273351 |
| MRC375 150mg | Other | Phase PHASE2 | Rheumatoid Arthritis | UNKNOWN | NCT01408602 |
| Matching Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | UNKNOWN | NCT01408602 |
| MRC375 | Other | Phase PHASE2 | Rheumatoid Arthritis | UNKNOWN | NCT01408602 |
| MP0112 | Other | Phase PHASE1 | Wet Age-Related Macular Degeneration | TERMINATED | NCT01086761 |
| MP0112 | Other | Phase PHASE1 | Diabetic Macular Edema | TERMINATED | NCT01042678 |
| Fluciclatide Injection | Other | Phase PHASE2 | Solid Tumors | COMPLETED | NCT00918281 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT01138111 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT01138111 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT01138111 |
| [123I]ß CIT | Other | Phase PHASE2 | Parkinsonian Syndrome | COMPLETED | NCT00129675 |
| [123I]ß CIT | Other | Phase PHASE2 | Parkinsonian Syndrome | COMPLETED | NCT00129675 |
| [123I]ß CIT | Other | Phase PHASE2 | Parkinsonian Syndrome | COMPLETED | NCT00129675 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00750282 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00750282 |
| Placebo | Other | Approved | Osteoarthritis Of Knee | UNKNOWN | NCT02280538 |
| Intra-Articular Hyaluronic Acid | Other | Approved | Osteoarthritis Of Knee | UNKNOWN | NCT02280538 |
| PET tracer (BAY94-9392) | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01186601 |
| PET tracer (BAY94-9392) | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01186601 |
| PET tracer (BAY94-9392) | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01186601 |
| BAY94-9392 | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01103310 |
| BAY94-9392 | Other | Phase PHASE1 | Diagnostic Imaging | COMPLETED | NCT01103310 |
| Placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02092896 |
| Liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02092896 |
| Nimotuzumab | Other | Phase PHASE2 | Diffuse Intrinsic Brainstem Gliomas | COMPLETED | NCT01145170 |
| Radiotherapy | Drug | Phase PHASE2 | Diffuse Intrinsic Brainstem Gliomas | COMPLETED | NCT01145170 |
| Nimotuzumab | Other | Phase PHASE2 | Diffuse Intrinsic Brainstem Gliomas | COMPLETED | NCT01145170 |
| Radiotherapy | Drug | Phase PHASE2 | Diffuse Intrinsic Brainstem Gliomas | COMPLETED | NCT01145170 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02243683 |
| AX-024.HCl | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02243683 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02243683 |
| AX-024.HCl | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02243683 |
| 99mTc-MIP-1404 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01654874 |
| 99mTc MIP 1404 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01615406 |
| 99mTc MIP 1404 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01615406 |
| 99mTc-MIP-1404 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01572701 |
| 99mTc-MIP-1404 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01572701 |
| 123I-MIP-1072 | Other | Preclinical | Prostate Cancer | WITHDRAWN | NCT01279785 |
| 99mTc MIP 1405 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01261754 |
| 99mTc MIP 1404 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01261754 |
| 99mTc MIP 1405 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01261754 |
| 99mTc MIP 1404 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01261754 |
| Ultratrace Iobenguane I 131 | Other | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT00992173 |
| Ultratrace Iobenguane I 131 | Other | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT00992173 |
| 90Y-SMT487 | Other | Phase PHASE2 | Malignant Carcinoid Tumor | WITHDRAWN | NCT00696930 |
| 90Y-SMT487 | Other | Phase PHASE2 | Malignant Carcinoid Tumor | WITHDRAWN | NCT00696930 |
| Placebo | Other | Approved | Postpartum Depression | COMPLETED | NCT02661789 |
| Goserelin 3.6 mg implant | Other | Approved | Postpartum Depression | COMPLETED | NCT02661789 |
| Placebo | Other | Approved | Postpartum Depression | COMPLETED | NCT02661789 |
| Goserelin 3.6 mg implant | Other | Approved | Postpartum Depression | COMPLETED | NCT02661789 |
| MT-3724 | Other | Phase PHASE1 | Chronic B-cell Lymphocytic Leukemia | WITHDRAWN | NCT02556346 |
| MT-3724 | Other | Phase PHASE1 | Chronic B-cell Lymphocytic Leukemia | WITHDRAWN | NCT02556346 |
| xTAG RPP | Other | Preclinical | Respiratory Tract Infection | COMPLETED | NCT01787227 |
| xTAG RPP | Other | Preclinical | Respiratory Tract Infection | COMPLETED | NCT01787227 |
| Iodofiltic acid I 123 | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00514501 |
| Iodofiltic acid I 123 | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00514501 |
| Patients | Other | Approved | Parkinson's Disease | UNKNOWN | NCT02753192 |
| Patients | Other | Approved | Parkinson's Disease | UNKNOWN | NCT02753192 |
| Patients | Other | Approved | Parkinson's Disease | UNKNOWN | NCT02753192 |
| Patients | Other | Approved | Parkinson's Disease | UNKNOWN | NCT02753192 |
| PA83-FhCMB | Other | Phase PHASE1 | Anthrax | COMPLETED | NCT02239172 |
| PA83-FhCMB | Other | Phase PHASE1 | Anthrax | COMPLETED | NCT02239172 |
| PA83-FhCMB | Other | Phase PHASE1 | Anthrax | COMPLETED | NCT02239172 |
| Saline | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01250795 |
| HAI-05 Influenza Vaccine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01250795 |
| Saline | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01250795 |
| HAI-05 Influenza Vaccine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01250795 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE3 | Alzheimer Disease | COMPLETED | NCT01020838 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE3 | Alzheimer Disease | COMPLETED | NCT01020838 |
| Florbetaben (BAY94-9172) | Other | Phase PHASE3 | Alzheimer Disease | COMPLETED | NCT01020838 |
| Placebo | Other | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT01048086 |
| Retinoic Acid | Other | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT01048086 |
| Placebo | Other | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT01048086 |
| Retinoic Acid | Other | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT01048086 |
| Ultratrace Iobenguane (MIBG) I 131 | Other | Phase PHASE1 | Pheochromocytoma | COMPLETED | NCT00458952 |
| Ultratrace Iobenguane (MIBG) I 131 | Other | Phase PHASE1 | Pheochromocytoma | COMPLETED | NCT00458952 |
| HAC1 Vaccine | Other | Phase PHASE1 | H1N1 Flu | COMPLETED | NCT01177202 |
| HAC1 Vaccine | Other | Phase PHASE1 | H1N1 Flu | COMPLETED | NCT01177202 |
| 18F-FSPG | Other | Phase PHASE1 | Brain Cancer | TERMINATED | NCT02370563 |
| 18F-FSPG | Other | Phase PHASE1 | Brain Cancer | TERMINATED | NCT02370563 |
| Sodium Acetate C11 PET/CT Imaging | Other | Phase PHASE2 | Gliomas | WITHDRAWN | NCT01961934 |
| Sodium Acetate C11 PET/CT Imaging | Other | Phase PHASE2 | Gliomas | WITHDRAWN | NCT01961934 |
| Treadmill | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT01856244 |
| treadmill walking | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT01856244 |
| Treadmill | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT01856244 |
| treadmill walking | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT01856244 |
| [18F]MNI-815 (MNI-815) | Other | Phase EARLY_PHASE1 | Alzheimer's Disease (AD) | COMPLETED | NCT02531360 |
| [18F]MNI-815 (MNI-815) | Other | Phase EARLY_PHASE1 | Alzheimer's Disease (AD) | COMPLETED | NCT02531360 |
| [123I]MNI-672 SPECT | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01859767 |
| [123I]MNI-672 SPECT | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01859767 |
| ALTROPANE® | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00397228 |
| ALTROPANE® | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00397228 |
| ALTROPANE® | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00397228 |
| Dihydroartemisinin-Piperaquine | Other | Preclinical | Plasmodium Falciparum Infection | COMPLETED | NCT02353494 |
| Drug: 99mTc-MIP-1404 | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01667536 |
| Drug: 99mTc-MIP-1404 | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01667536 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT02017340 |
| Nilvadipine | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT02017340 |
| [18F]T807 | Other | Phase PHASE1 | Alzheimer's Disease (AD) | COMPLETED | NCT02370524 |
| [18F]T807 | Other | Phase PHASE1 | Alzheimer's Disease (AD) | COMPLETED | NCT02370524 |
| [18F]T807 | Other | Phase PHASE1 | Alzheimer's Disease (AD) | COMPLETED | NCT02370524 |
| Pfs25 VLP- FhCMB | Other | Phase PHASE1 | Malaria | COMPLETED | NCT02013687 |
| Pfs25 VLP- FhCMB | Other | Phase PHASE1 | Malaria | COMPLETED | NCT02013687 |
| Administering three additional MRI images | Other | Preclinical | Multiple Myeloma | TERMINATED | NCT01018927 |
| Administering three additional MRI images | Other | Preclinical | Multiple Myeloma | TERMINATED | NCT01018927 |
| FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT | Other | Preclinical | High Grade Glioma | COMPLETED | NCT01240161 |
| UltratraceTM Iobenguane I 131 Therapy | Drug | Phase PHASE2 | Neuroblastoma | COMPLETED | NCT00659984 |
| UltratraceTM Iobenguane I 131 Imaging | Other | Phase PHASE2 | Neuroblastoma | COMPLETED | NCT00659984 |
| UltratraceTM Iobenguane I 131 Therapy | Drug | Phase PHASE2 | Neuroblastoma | COMPLETED | NCT00659984 |
| UltratraceTM Iobenguane I 131 Imaging | Other | Phase PHASE2 | Neuroblastoma | COMPLETED | NCT00659984 |
| No intervention, observational study. | Other | Preclinical | Lynch Syndrome | RECRUITING | NCT03303833 |
| No intervention, observational study. | Other | Preclinical | Lynch Syndrome | RECRUITING | NCT03303833 |
| Heart and spleen tissue | Other | Preclinical | Sudden Death | UNKNOWN | NCT02920203 |
| Heart and spleen tissue | Other | Preclinical | Sudden Death | UNKNOWN | NCT02920203 |
| [18F]MNI-968 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03142724 |
| [18F]MNI-968 | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT03082768 |
| [18F]MNI-968 | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT03082768 |
| Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease | Drug | Phase PHASE1 | Graft vs Host Disease | UNKNOWN | NCT02385019 |
| Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease | Drug | Phase PHASE1 | Graft vs Host Disease | UNKNOWN | NCT02385019 |
| dihydroartemisinin-piperaquine | Other | Approved | Plasmodium Falciparum Malaria | COMPLETED | NCT02001428 |
| dihydroartemisinin-piperaquine | Other | Approved | Plasmodium Falciparum Malaria | COMPLETED | NCT02001428 |
| Virological Monitoring | Other | Approved | HIV Infection | COMPLETED | NCT01317498 |
| Standard Care | Other | Approved | HIV Infection | COMPLETED | NCT01317498 |
| Virological Monitoring | Other | Approved | HIV Infection | COMPLETED | NCT01317498 |
| Standard Care | Other | Approved | HIV Infection | COMPLETED | NCT01317498 |
| Virological Monitoring | Other | Approved | HIV Infection | COMPLETED | NCT01317498 |
| Standard Care | Other | Approved | HIV Infection | COMPLETED | NCT01317498 |
| Olive oil | Other | Phase PHASE4 | Kidney Failure, Chronic | COMPLETED | NCT02214563 |
| Cholecalciferol | Other | Phase PHASE4 | Kidney Failure, Chronic | COMPLETED | NCT02214563 |
| Olive oil | Other | Phase PHASE4 | Kidney Failure, Chronic | COMPLETED | NCT02214563 |
| Cholecalciferol | Other | Phase PHASE4 | Kidney Failure, Chronic | COMPLETED | NCT02214563 |
| ARIES Bordetella Assay | Other | Approved | Bordetella Infections | COMPLETED | NCT02862262 |
| ARIES Bordetella Assay | Other | Approved | Bordetella Infections | COMPLETED | NCT02862262 |
| ARIES Bordetella Assay | Other | Approved | Bordetella Infections | COMPLETED | NCT02862262 |
| Multicomponent training | Other | Approved | Aging | COMPLETED | NCT03455179 |
| High-speed resistance training | Other | Approved | Aging | COMPLETED | NCT03455179 |
| Slow-speed traditional resistance training | Other | Approved | Aging | COMPLETED | NCT03455179 |
| Multicomponent training | Other | Approved | Aging | COMPLETED | NCT03455179 |
| High-speed resistance training | Other | Approved | Aging | COMPLETED | NCT03455179 |
| Slow-speed traditional resistance training | Other | Approved | Aging | COMPLETED | NCT03455179 |
| motor learning | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| rest | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| aerobic exercise | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| motor learning | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| rest | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| aerobic exercise | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| motor learning | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| rest | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| aerobic exercise | Other | Approved | Parkinson Disease | COMPLETED | NCT03245216 |
| Hypoxia | Other | Approved | Energy Metabolism | COMPLETED | NCT03121885 |
| 30-minute movement activity | Other | Approved | Energy Metabolism | COMPLETED | NCT03121885 |
| Hypoxia | Other | Approved | Energy Metabolism | COMPLETED | NCT03121885 |
| 30-minute movement activity | Other | Approved | Energy Metabolism | COMPLETED | NCT03121885 |
| Ultratrace Iobenguane I131 | Other | Preclinical | Pheochromocytoma | APPROVED_FOR_MARKETING | NCT02961491 |
| Ultratrace Iobenguane I131 | Other | Preclinical | Pheochromocytoma | APPROVED_FOR_MARKETING | NCT02961491 |
| Ultratrace Iobenguane I131 | Other | Preclinical | Pheochromocytoma | APPROVED_FOR_MARKETING | NCT02961491 |
| C11-Sodium Acetate | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01530269 |
| C11-Sodium Acetate | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01530269 |
| Sodium Acetate C11 | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01304485 |
| Sodium Acetate C11 | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01304485 |
| Conventional wound dressings | Other | Approved | Wounds, Gunshot | COMPLETED | NCT02444598 |
| Vaccum Assisted Closure device | Device | Approved | Wounds, Gunshot | COMPLETED | NCT02444598 |
| Morphine | Other | Phase PHASE4 | Colon Cancer | COMPLETED | NCT02314871 |
| Piritramide | Other | Phase PHASE4 | Colon Cancer | COMPLETED | NCT02314871 |
| Epidural analgesia | Other | Phase PHASE4 | Colon Cancer | COMPLETED | NCT02314871 |
| Morphine | Other | Phase PHASE4 | Colon Cancer | COMPLETED | NCT02314871 |
| Piritramide | Other | Phase PHASE4 | Colon Cancer | COMPLETED | NCT02314871 |
| Epidural analgesia | Other | Phase PHASE4 | Colon Cancer | COMPLETED | NCT02314871 |
| 123-I MNI-187 Injection and Imaging Procedures | Procedure | Phase PHASE1 | Alzheimers Disease | COMPLETED | NCT00456417 |
| 123-I MNI-187 Injection and Imaging Procedures | Procedure | Phase PHASE1 | Alzheimers Disease | COMPLETED | NCT00456417 |
| 123-I MNI-187 Injection and Imaging Procedures | Procedure | Phase PHASE1 | Alzheimers Disease | COMPLETED | NCT00456417 |
| [18F]PBR06 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03876002 |
| [18F]PBR06 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03876002 |
| Placebo | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT03898505 |
| AvoMax (High Dose) | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT03898505 |
| AvoMax (Low Dose) | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT03898505 |
| Placebo | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT03898505 |
| AvoMax (High Dose) | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT03898505 |
| AvoMax (Low Dose) | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT03898505 |
| MNI-330 as a brain SPECT tracer of Beta-Amyloid | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT00657813 |
| MNI-330 as a brain SPECT tracer of Beta-Amyloid | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT00657813 |
| [123I]ß-CIT and SPECT imaging | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00132626 |
| [123I]ß-CIT and SPECT imaging | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00132626 |
| [123I]ß-CIT and SPECT imaging | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00132626 |
| Whole-Body Planar and pelvic SPECT/CT scan | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT02615067 |
| 99mTc-MIP-1404 Injection | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT02615067 |
| Whole-Body Planar and pelvic SPECT/CT scan | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT02615067 |
| 99mTc-MIP-1404 Injection | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT02615067 |
| Gluten-free diet | Other | Approved | Reduction of Intestinal Inflammatory Activity | COMPLETED | NCT04006886 |
| Gluten-free diet | Other | Approved | Reduction of Intestinal Inflammatory Activity | COMPLETED | NCT04006886 |
| medical history, blood and urine tests | Other | Preclinical | Aging Disorder | UNKNOWN | NCT04026815 |
| medical history, blood and urine tests | Other | Preclinical | Aging Disorder | UNKNOWN | NCT04026815 |
| MP0250 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02194426 |
| Computed Tomography (CT) of the heart | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Inflammatory and lipid markers | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Genetic Mutations | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Computed Tomography (CT) of the heart | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Inflammatory and lipid markers | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Genetic Mutations | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Computed Tomography (CT) of the heart | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Inflammatory and lipid markers | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Genetic Mutations | Other | Approved | MDS | UNKNOWN | NCT04110925 |
| Erythropoietin human recombinant (EPOrh) | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT01010802 |
| Erythropoietin human recombinant (EPOrh) | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT01010802 |
| MT-3724 | Other | Preclinical | Non-Hodgkin's B-cell Lymphoma | NO_LONGER_AVAILABLE | NCT02715843 |
| MT-3724 | Other | Preclinical | Non-Hodgkin's B-cell Lymphoma | NO_LONGER_AVAILABLE | NCT02715843 |
| CTC/DTC count | Other | Approved | Colorectal Cancer | COMPLETED | NCT03337347 |
| CTC/DTC count | Other | Approved | Colorectal Cancer | COMPLETED | NCT03337347 |
| CTC/DTC count | Other | Approved | Colorectal Cancer | COMPLETED | NCT03337347 |
| Duloxetine | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT02869035 |
| Escitalopram | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT02869035 |
| Duloxetine | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT02869035 |
| Escitalopram | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT02869035 |
| Cabozantinib 60 MG | Other | Phase PHASE2 | Non Small Cell Lung Cancer | UNKNOWN | NCT04131543 |
| Cabozantinib 40 MG | Other | Phase PHASE2 | Non Small Cell Lung Cancer | UNKNOWN | NCT04131543 |
| Cabozantinib 20 MG | Other | Phase PHASE2 | Non Small Cell Lung Cancer | UNKNOWN | NCT04131543 |
| Self-sampling using Evalyn Brush | Other | Approved | Cervical Cancer | COMPLETED | NCT04133610 |
| Self-sampling using digene HC2 DNA Collection Device | Device | Approved | Cervical Cancer | COMPLETED | NCT04133610 |
| Self-sampling using Evalyn Brush | Other | Approved | Cervical Cancer | COMPLETED | NCT04133610 |
| Self-sampling using digene HC2 DNA Collection Device | Device | Approved | Cervical Cancer | COMPLETED | NCT04133610 |
| 11C-choline Injection | Other | Phase PHASE3 | Metastatic Prostate Cancer | COMPLETED | NCT02260817 |
| 11C-choline Injection | Other | Phase PHASE3 | Metastatic Prostate Cancer | COMPLETED | NCT02260817 |
| lifestyle counseling | Other | Approved | Fertility Disorders | COMPLETED | NCT04012385 |
| lifestyle counseling | Other | Approved | Fertility Disorders | COMPLETED | NCT04012385 |
| Ultratrace® Iobenguane I131 | Other | Phase PHASE2 | Pheochromocytoma | UNKNOWN | NCT00874614 |
| motor learning | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| rest | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| aerobic exercise | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| motor learning | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| rest | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| aerobic exercise | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| motor learning | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| rest | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| aerobic exercise | Other | Approved | Parkinson Disease | COMPLETED | NCT03886090 |
| this study is non- interventional | Other | Preclinical | COVID-19 | UNKNOWN | NCT04341168 |
| this study is non- interventional | Other | Preclinical | COVID-19 | UNKNOWN | NCT04341168 |
| Vit B12 | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| Statin | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| Aspirin | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| DLBS1033 | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| Vit B12 | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| Statin | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| Aspirin | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| DLBS1033 | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| Vit B12 | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| Statin | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| Aspirin | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| DLBS1033 | Other | Phase PHASE2 | Ischemic Stroke | UNKNOWN | NCT04425590 |
| FDA-cleared NAATs | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT03970850 |
| NeuMoDx CT/NG Assay | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT03970850 |
| FDA-cleared NAATs | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT03970850 |
| NeuMoDx CT/NG Assay | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT03970850 |
| Convalescent plasma | Other | Phase PHASE1 | Convalescence | COMPLETED | NCT04407208 |
| Convalescent plasma | Other | Phase PHASE1 | Convalescence | COMPLETED | NCT04407208 |
| Convalescent plasma | Other | Phase PHASE1 | Convalescence | COMPLETED | NCT04407208 |
| NeuroEPO | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT04110678 |
| NeuroEPO | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT04110678 |
| Placebo | Other | Approved | Abdominal Obesity Metabolic Syndrome | COMPLETED | NCT02954588 |
| Pyridoxamine | Other | Approved | Abdominal Obesity Metabolic Syndrome | COMPLETED | NCT02954588 |
| Placebo | Other | Approved | Abdominal Obesity Metabolic Syndrome | COMPLETED | NCT02954588 |
| Pyridoxamine | Other | Approved | Abdominal Obesity Metabolic Syndrome | COMPLETED | NCT02954588 |
| Placebo | Other | Approved | Abdominal Obesity Metabolic Syndrome | COMPLETED | NCT02954588 |
| Pyridoxamine | Other | Approved | Abdominal Obesity Metabolic Syndrome | COMPLETED | NCT02954588 |
| Progenitor Stem Cell Culture | Other | Phase PHASE2 | Alzheimer's Disease | WITHDRAWN | NCT00927108 |
| Progenitor Stem Cell Culture | Other | Phase PHASE2 | Alzheimer's Disease | WITHDRAWN | NCT00927108 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02065713 |
| Methotrexate | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02065713 |
| Golimumab | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02065713 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02065713 |
| Methotrexate | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02065713 |
| Golimumab | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02065713 |
| Whole Genome Sequencing | Other | Approved | Hereditary Disease | COMPLETED | NCT03829176 |
| Pregnancy | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT03795688 |
| Pregnancy | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT03795688 |
| Niacin | Other | Approved | Mitochondrial Myopathies | COMPLETED | NCT04538521 |
| Cyclophosphamide | Other | Phase PHASE1 | Metastatic Breast Cancer | UNKNOWN | NCT03749850 |
| MR-HIFU induced hyperthermia | Other | Phase PHASE1 | Metastatic Breast Cancer | UNKNOWN | NCT03749850 |
| LTLD | Other | Phase PHASE1 | Metastatic Breast Cancer | UNKNOWN | NCT03749850 |
| Cyclophosphamide | Other | Phase PHASE1 | Metastatic Breast Cancer | UNKNOWN | NCT03749850 |
| MR-HIFU induced hyperthermia | Other | Phase PHASE1 | Metastatic Breast Cancer | UNKNOWN | NCT03749850 |
| LTLD | Other | Phase PHASE1 | Metastatic Breast Cancer | UNKNOWN | NCT03749850 |
| Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa | Other | Phase PHASE2 | Retinitis Pigmentosa (RP) | UNKNOWN | NCT04763369 |
| Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa | Other | Phase PHASE2 | Retinitis Pigmentosa (RP) | UNKNOWN | NCT04763369 |
| Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa | Other | Phase PHASE2 | Retinitis Pigmentosa (RP) | UNKNOWN | NCT04763369 |
| Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa | Other | Phase PHASE2 | Retinitis Pigmentosa (RP) | UNKNOWN | NCT04763369 |
| Cardiological evaluation | Other | Preclinical | Fabry Disease | COMPLETED | NCT03838237 |
| Dermal nuclear magnetic resonance (NMR)-profile measurement | Other | Approved | Exposure to Magnetic Field | TERMINATED | NCT02934009 |
| Dermal nuclear magnetic resonance (NMR)-profile measurement | Other | Approved | Exposure to Magnetic Field | TERMINATED | NCT02934009 |
| Placebo | Other | Phase PHASE2 | Subjective Cognitive Decline (SCD) | COMPLETED | NCT03094546 |
| Polyamine | Other | Phase PHASE2 | Subjective Cognitive Decline (SCD) | COMPLETED | NCT03094546 |
| Placebo | Other | Phase PHASE2 | Subjective Cognitive Decline (SCD) | COMPLETED | NCT03094546 |
| Polyamine | Other | Phase PHASE2 | Subjective Cognitive Decline (SCD) | COMPLETED | NCT03094546 |
| Placebo supplementation | Other | Phase PHASE2 | Subjective Cognitive Decline | COMPLETED | NCT02755246 |
| Polyamine supplementation | Other | Phase PHASE2 | Subjective Cognitive Decline | COMPLETED | NCT02755246 |
| Placebo supplementation | Other | Phase PHASE2 | Subjective Cognitive Decline | COMPLETED | NCT02755246 |
| Polyamine supplementation | Other | Phase PHASE2 | Subjective Cognitive Decline | COMPLETED | NCT02755246 |
| Specialist review | Other | Approved | Parkinson's Disease | COMPLETED | NCT02333175 |
| Specialist review | Other | Approved | Parkinson's Disease | COMPLETED | NCT02333175 |
| Specialist review | Other | Approved | Parkinson's Disease | COMPLETED | NCT02333175 |
| Positron Emission Tomography (PET) /Computerized tomography (CT) | Other | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| 124I-MIBG (carrier added) | Other | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added) | Other | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| Positron Emission Tomography (PET) /Computerized tomography (CT) | Other | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| 124I-MIBG (carrier added) | Other | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added) | Other | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| Convalescent plasma treatment | Drug | Phase PHASE2 | COVID-19 | UNKNOWN | NCT04873414 |
| Convalescent plasma treatment | Drug | Phase PHASE2 | COVID-19 | UNKNOWN | NCT04873414 |
| Group D:Placebo oropharyngeal spray + Placebo taken PO | Other | Approved | COVID | COMPLETED | NCT04420260 |
| Group A: oropharygeal spray and immunostimulant emulsion | Other | Approved | COVID | COMPLETED | NCT04420260 |
| Group D:Placebo oropharyngeal spray + Placebo taken PO | Other | Approved | COVID | COMPLETED | NCT04420260 |
| Group A: oropharygeal spray and immunostimulant emulsion | Other | Approved | COVID | COMPLETED | NCT04420260 |
| 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | Other | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | Other | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | Other | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | Other | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | Other | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | Other | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | Other | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | Other | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| MP0250 plus BOR+DEX | Other | Phase PHASE1 | Multiple Myeloma in Relapse | COMPLETED | NCT03136653 |
| dental implant | Other | Approved | Dental Implant Failure Nos | UNKNOWN | NCT03459547 |
| dental implant | Other | Approved | Dental Implant Failure Nos | UNKNOWN | NCT03459547 |
| Placebo | Other | Phase PHASE3 | Alzheimer Disease | NOT_YET_RECRUITING | NCT05143528 |
| Nilotinib BE 112 mg | Other | Phase PHASE3 | Alzheimer Disease | NOT_YET_RECRUITING | NCT05143528 |
| Nilotinib BE 84mg | Other | Phase PHASE3 | Alzheimer Disease | NOT_YET_RECRUITING | NCT05143528 |
| Placebo | Other | Phase PHASE3 | Alzheimer Disease | NOT_YET_RECRUITING | NCT05143528 |
| Nilotinib BE 112 mg | Other | Phase PHASE3 | Alzheimer Disease | NOT_YET_RECRUITING | NCT05143528 |
| Nilotinib BE 84mg | Other | Phase PHASE3 | Alzheimer Disease | NOT_YET_RECRUITING | NCT05143528 |
| 89Zr-trastuzumab | Other | Phase PHASE2 | HER2-positive Solid Tumor | WITHDRAWN | NCT04757090 |
| 89Zr-trastuzumab | Other | Phase PHASE2 | HER2-positive Solid Tumor | WITHDRAWN | NCT04757090 |
| Observation | Other | Preclinical | Choroideremia | TERMINATED | NCT02994368 |
| Observation | Other | Preclinical | Choroideremia | TERMINATED | NCT02994368 |
| 99mTc-Duramycin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05177640 |
| 99mTc-Duramycin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05177640 |
| NIR optical imaging camera | Other | Approved | Hypoparathyroidism Postprocedural | UNKNOWN | NCT04193332 |
| NIR optical imaging camera | Other | Approved | Hypoparathyroidism Postprocedural | UNKNOWN | NCT04193332 |
| Medical examination | Other | Preclinical | Type 1 Diabetes | COMPLETED | NCT04698122 |
| Questionnaire | Other | Preclinical | Type 1 Diabetes | COMPLETED | NCT04698122 |
| Biological sample collection | Other | Preclinical | Type 1 Diabetes | COMPLETED | NCT04698122 |
| Medical examination | Other | Preclinical | Type 1 Diabetes | COMPLETED | NCT04698122 |
| Questionnaire | Other | Preclinical | Type 1 Diabetes | COMPLETED | NCT04698122 |
| Biological sample collection | Other | Preclinical | Type 1 Diabetes | COMPLETED | NCT04698122 |
| Propranolol | Other | Phase PHASE2 | Cerebral Cavernous Malformation | COMPLETED | NCT03589014 |
| Propranolol | Other | Phase PHASE2 | Cerebral Cavernous Malformation | COMPLETED | NCT03589014 |
| Placebo | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT04870164 |
| Ensovibep | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT04870164 |
| Medical examination | Other | Preclinical | Metabolic Syndrome | COMPLETED | NCT04698096 |
| Questionnaire | Other | Preclinical | Metabolic Syndrome | COMPLETED | NCT04698096 |
| Biological sample collection | Other | Preclinical | Metabolic Syndrome | COMPLETED | NCT04698096 |
| Medical examination | Other | Preclinical | Metabolic Syndrome | COMPLETED | NCT04698096 |
| Questionnaire | Other | Preclinical | Metabolic Syndrome | COMPLETED | NCT04698096 |
| Biological sample collection | Other | Preclinical | Metabolic Syndrome | COMPLETED | NCT04698096 |
| [123I]β-CIT | Other | Phase PHASE2 | Parkinson Disease | UNKNOWN | NCT00387075 |
| [123I]β-CIT and SPECT imaging | Other | Phase PHASE2 | Parkinson Disease | UNKNOWN | NCT00387075 |
| [123I]β-CIT | Other | Phase PHASE2 | Parkinson Disease | UNKNOWN | NCT00387075 |
| [123I]β-CIT and SPECT imaging | Other | Phase PHASE2 | Parkinson Disease | UNKNOWN | NCT00387075 |
| [123I]β-CIT | Other | Phase PHASE2 | Parkinson Disease | UNKNOWN | NCT00387075 |
| [123I]β-CIT and SPECT imaging | Other | Phase PHASE2 | Parkinson Disease | UNKNOWN | NCT00387075 |
| Medical examination | Other | Preclinical | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | COMPLETED | NCT04689074 |
| Questionnaire | Other | Preclinical | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | COMPLETED | NCT04689074 |
| Biological sample collection | Other | Preclinical | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | COMPLETED | NCT04689074 |
| Medical examination | Other | Preclinical | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | COMPLETED | NCT04689074 |
| Questionnaire | Other | Preclinical | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | COMPLETED | NCT04689074 |
| Biological sample collection | Other | Preclinical | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | COMPLETED | NCT04689074 |
| Medical examination | Other | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT04698161 |
| Questionnaire | Other | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT04698161 |
| Biological sample collection | Other | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT04698161 |
| Medical examination | Other | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT04698161 |
| Questionnaire | Other | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT04698161 |
| Biological sample collection | Other | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT04698161 |
| Medical examination | Other | Preclinical | Clostridium Difficile Infection | COMPLETED | NCT04698148 |
| Questionnaire | Other | Preclinical | Clostridium Difficile Infection | COMPLETED | NCT04698148 |
| Biological sample collection | Other | Preclinical | Clostridium Difficile Infection | COMPLETED | NCT04698148 |
| Medical examination | Other | Preclinical | Clostridium Difficile Infection | COMPLETED | NCT04698148 |
| Questionnaire | Other | Preclinical | Clostridium Difficile Infection | COMPLETED | NCT04698148 |
| Biological sample collection | Other | Preclinical | Clostridium Difficile Infection | COMPLETED | NCT04698148 |
| MT-3724 | Other | Phase PHASE2 | Non-hodgkin Lymphoma | TERMINATED | NCT03645395 |
| Oxaliplatin | Other | Phase PHASE2 | Non-hodgkin Lymphoma,B Cell | TERMINATED | NCT03488251 |
| Gemcitabine | Other | Phase PHASE2 | Non-hodgkin Lymphoma,B Cell | TERMINATED | NCT03488251 |
| MT-3724 | Other | Phase PHASE2 | Non-hodgkin Lymphoma,B Cell | TERMINATED | NCT03488251 |
| Oxaliplatin | Other | Phase PHASE2 | Non-hodgkin Lymphoma,B Cell | TERMINATED | NCT03488251 |
| Gemcitabine | Other | Phase PHASE2 | Non-hodgkin Lymphoma,B Cell | TERMINATED | NCT03488251 |
| MT-3724 | Other | Phase PHASE2 | Non-hodgkin Lymphoma,B Cell | TERMINATED | NCT03488251 |
| MT-3724 Phase 2 | Other | Phase PHASE1 | Non-Hodgkin's B-cell Lymphoma | TERMINATED | NCT02361346 |
| MT-3724 Phase 1 | Other | Phase PHASE1 | Non-Hodgkin's B-cell Lymphoma | TERMINATED | NCT02361346 |
| MT-3724 Phase 2 | Other | Phase PHASE1 | Non-Hodgkin's B-cell Lymphoma | TERMINATED | NCT02361346 |
| MT-3724 Phase 1 | Other | Phase PHASE1 | Non-Hodgkin's B-cell Lymphoma | TERMINATED | NCT02361346 |
| Laparoscopic total nephrectomy control arm | Other | Approved | Renal Cell Carcinoma | COMPLETED | NCT05070637 |
| Conventional laparoscopic radical nephrectomy | Other | Approved | Renal Cell Carcinoma | COMPLETED | NCT05070637 |
| No-touch laparoscopic radical nephrectomy | Other | Approved | Renal Cell Carcinoma | COMPLETED | NCT05070637 |
| Laparoscopic total nephrectomy control arm | Other | Approved | Renal Cell Carcinoma | COMPLETED | NCT05070637 |
| Conventional laparoscopic radical nephrectomy | Other | Approved | Renal Cell Carcinoma | COMPLETED | NCT05070637 |
| No-touch laparoscopic radical nephrectomy | Other | Approved | Renal Cell Carcinoma | COMPLETED | NCT05070637 |
| Observation | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT05032352 |
| Adjuvant | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT05032352 |
| Observation | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT05032352 |
| Adjuvant | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT05032352 |
| Cellular immunity | Other | Preclinical | COVID-19 | COMPLETED | NCT05096962 |
| Quantitative analysis of SARS-CoV-2 antibodies | Other | Preclinical | COVID-19 | COMPLETED | NCT05096962 |
| Cellular immunity | Other | Preclinical | COVID-19 | COMPLETED | NCT05096962 |
| Quantitative analysis of SARS-CoV-2 antibodies | Other | Preclinical | COVID-19 | COMPLETED | NCT05096962 |
| MP0310 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04049903 |
| Lutetium [177Lu] oxodotreotide/dotatate | Other | Preclinical | Neuroendocrine Tumors | RECRUITING | NCT04949282 |
| Lutetium [177Lu] oxodotreotide/dotatate | Other | Preclinical | Neuroendocrine Tumors | RECRUITING | NCT04949282 |
| Preoperative chemotherapy | Drug | Phase PHASE2 | Triple-negative Breast Cancer | UNKNOWN | NCT04248998 |
| Metformin | Other | Phase PHASE2 | Triple-negative Breast Cancer | UNKNOWN | NCT04248998 |
| Fasting-mimicking diet | Other | Phase PHASE2 | Triple-negative Breast Cancer | UNKNOWN | NCT04248998 |
| Preoperative chemotherapy | Drug | Phase PHASE2 | Triple-negative Breast Cancer | UNKNOWN | NCT04248998 |
| Metformin | Other | Phase PHASE2 | Triple-negative Breast Cancer | UNKNOWN | NCT04248998 |
| Fasting-mimicking diet | Other | Phase PHASE2 | Triple-negative Breast Cancer | UNKNOWN | NCT04248998 |
| Atezolizumab | Other | Phase PHASE2 | Small Cell Lung Carcinoma | NOT_YET_RECRUITING | NCT05703997 |
| Cyclic, 5-day calorie restriction | Other | Phase PHASE2 | Small Cell Lung Carcinoma | NOT_YET_RECRUITING | NCT05703997 |
| Atezolizumab | Other | Phase PHASE2 | Small Cell Lung Carcinoma | NOT_YET_RECRUITING | NCT05703997 |
| Cyclic, 5-day calorie restriction | Other | Phase PHASE2 | Small Cell Lung Carcinoma | NOT_YET_RECRUITING | NCT05703997 |
| Serological screen and treat | Other | Approved | Malaria, Vivax | UNKNOWN | NCT04223674 |
| Serological screen and treat | Other | Approved | Malaria, Vivax | UNKNOWN | NCT04223674 |
| MP0250 DARPin® drug candidate, Osimertinib | Drug | Phase PHASE1 | EGFR-mutated NSCLC (Disorder) | TERMINATED | NCT03418532 |
| Glucagon | Other | Approved | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT04859322 |
| Glucagon | Other | Approved | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT04859322 |
| Glucagon | Other | Approved | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT04859322 |
| Niacin | Other | Approved | Mitochondrial Myopathies | COMPLETED | NCT03973203 |
| Longevity Diet (LD) + Fasting-mimicking Diet (FMD) | Other | Approved | Overweight | UNKNOWN | NCT05698654 |
| Fasting-mimicking diet (FMD) | Other | Approved | Overweight | UNKNOWN | NCT05698654 |
| Longevity Diet (LD) + Fasting-mimicking Diet (FMD) | Other | Approved | Overweight | UNKNOWN | NCT05698654 |
| Fasting-mimicking diet (FMD) | Other | Approved | Overweight | UNKNOWN | NCT05698654 |
| MT-5111 (experimental study drug) | Drug | Phase PHASE1 | HER2-positive Solid Cancers | TERMINATED | NCT04029922 |
| MT-5111 (experimental study drug) | Drug | Phase PHASE1 | HER2-positive Solid Cancers | TERMINATED | NCT04029922 |
| HPP/VE Choko | Other | Approved | Dementia | UNKNOWN | NCT05343611 |
| HPP Choko | Other | Approved | Dementia | UNKNOWN | NCT05343611 |
| Combination of High Protein Diet and Physical Exercise protocol | Other | Approved | Dementia | UNKNOWN | NCT05343611 |
| HPP/VE Choko | Other | Approved | Dementia | UNKNOWN | NCT05343611 |
| HPP Choko | Other | Approved | Dementia | UNKNOWN | NCT05343611 |
| Combination of High Protein Diet and Physical Exercise protocol | Other | Approved | Dementia | UNKNOWN | NCT05343611 |
| Niraparib | Other | Phase PHASE2 | Metastatic Colorectal Cancer | WITHDRAWN | NCT05412706 |
| Niraparib | Other | Phase PHASE2 | Metastatic Colorectal Cancer | WITHDRAWN | NCT05412706 |
| Ultra-micronized Palmitoylethanolamide (PEA) | Other | Approved | Clinical High Risk for Psychosis | UNKNOWN | NCT06037993 |
| Ultra-micronized Palmitoylethanolamide (PEA) | Other | Approved | Clinical High Risk for Psychosis | UNKNOWN | NCT06037993 |
| FOLFIRI | Other | Phase PHASE2 | Colon Cancer | UNKNOWN | NCT04259944 |
| Capecitabine | Other | Phase PHASE2 | Colon Cancer | UNKNOWN | NCT04259944 |
| CAPOX | Other | Phase PHASE2 | Colon Cancer | UNKNOWN | NCT04259944 |
| Rapid Diagnostic Test | Other | Preclinical | Malaria | COMPLETED | NCT05444790 |
| Rapid Diagnostic Test | Other | Preclinical | Malaria | COMPLETED | NCT05444790 |
| Rapid diagnostic test | Other | Preclinical | Malaria | COMPLETED | NCT05085301 |
| Rapid diagnostic test | Other | Preclinical | Malaria | COMPLETED | NCT05085301 |
| Rapid diagnostic test | Other | Preclinical | Malaria | COMPLETED | NCT05085301 |
| Transcranial doppler | Other | Preclinical | Stroke | COMPLETED | NCT01709045 |
| Ultrasound | Other | Preclinical | Stroke | COMPLETED | NCT01709045 |
| Dual-Energy Computed Tomography (DECT) | Other | Preclinical | Stroke | COMPLETED | NCT01709045 |
| Magnetic Resonance Imaging (MRI) | Other | Preclinical | Stroke | COMPLETED | NCT01709045 |
| Transcranial doppler | Other | Preclinical | Stroke | COMPLETED | NCT01709045 |
| Ultrasound | Other | Preclinical | Stroke | COMPLETED | NCT01709045 |
| Dual-Energy Computed Tomography (DECT) | Other | Preclinical | Stroke | COMPLETED | NCT01709045 |
| Magnetic Resonance Imaging (MRI) | Other | Preclinical | Stroke | COMPLETED | NCT01709045 |
| Assessment of Melatonin level | Other | Preclinical | ICU Delirium | COMPLETED | NCT04721613 |
| Assessment of Melatonin level | Other | Preclinical | ICU Delirium | COMPLETED | NCT04721613 |
| Assessment of Melatonin level | Other | Preclinical | ICU Delirium | COMPLETED | NCT04721613 |
| Piritramid | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700541 |
| Morphine | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700541 |
| Piritramid | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700541 |
| Morphine | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700541 |
| Piritramid | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700541 |
| Morphine | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700541 |
| Epidural | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700411 |
| Piritramid | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700411 |
| Morphine | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700411 |
| Epidural | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700411 |
| Piritramid | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700411 |
| Morphine | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT03700411 |
| MT-0169 | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT04017130 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780463 |
| Placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780463 |
| MP0420 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780463 |
| [18F] PI-2620 Tau Ligand | Other | Phase PHASE1 | Chronic Traumatic Encephalopathy | UNKNOWN | NCT05490576 |
| [18F] PI-2620 Tau Ligand | Other | Phase PHASE1 | Chronic Traumatic Encephalopathy | UNKNOWN | NCT05490576 |
| Atezolizumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT03976518 |
| Atezolizumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT03976518 |
| Amino Acid Solution | Other | Phase PHASE1 | Neuroendocrine Tumors | UNKNOWN | NCT05475210 |
| 177Lu-DOTA-EB-TATE | Other | Phase PHASE1 | Neuroendocrine Tumors | UNKNOWN | NCT05475210 |
| Amino Acid Solution | Other | Phase PHASE1 | Neuroendocrine Tumors | UNKNOWN | NCT05475210 |
| 177Lu-DOTA-EB-TATE | Other | Phase PHASE1 | Neuroendocrine Tumors | UNKNOWN | NCT05475210 |
| Personalized drug combination | Drug | Phase EARLY_PHASE1 | Recurrent Glioblastoma | RECRUITING | NCT05043701 |
| 4D-310 | Other | Phase PHASE1 | Fabry Disease | ACTIVE_NOT_RECRUITING | NCT04519749 |
| 4D-310 | Other | Phase PHASE1 | Fabry Disease | ACTIVE_NOT_RECRUITING | NCT04519749 |
| CRT-D (Medtronic) | Other | Preclinical | Heart Failure | COMPLETED | NCT01519908 |
| CRT-D (Medtronic) | Other | Preclinical | Heart Failure | COMPLETED | NCT01519908 |
| EMI-137 | Other | Phase PHASE2 | Colonic Cancer | COMPLETED | NCT03360461 |
| EMI-137 | Other | Phase PHASE2 | Colonic Cancer | COMPLETED | NCT03360461 |
| [18F]PI-2620 | Other | Phase PHASE1 | Mild Traumatic Brain Injury | TERMINATED | NCT05337774 |
| [18F]PI-2620 | Other | Phase PHASE1 | Mild Traumatic Brain Injury | TERMINATED | NCT05337774 |
| Echocardiography | Other | Preclinical | Diastolic Dysfunction | COMPLETED | NCT05552521 |
| Echocardiography | Other | Preclinical | Diastolic Dysfunction | COMPLETED | NCT05552521 |
| Support Group | Other | Approved | Breast Cancer Female | RECRUITING | NCT05642897 |
| Mind | Other | Approved | Breast Cancer Female | RECRUITING | NCT05642897 |
| 18F-GP1 | Other | Preclinical | Thrombosis Cardiac | COMPLETED | NCT04073875 |
| 18F-GP1 | Other | Preclinical | Thrombosis Cardiac | COMPLETED | NCT04073875 |
| Water-based resistance training program at moderate intensity (WMI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at moderate intensity (MI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at moderate-high intensity (MHI-bands) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at high intensity (HI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Water-based resistance training program at moderate intensity (WMI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at moderate intensity (MI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at moderate-high intensity (MHI-bands) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at high intensity (HI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Water-based resistance training program at moderate intensity (WMI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at moderate intensity (MI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at moderate-high intensity (MHI-bands) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| Elastic band-based resistance training program at high intensity (HI) | Other | Approved | Aging | COMPLETED | NCT06618469 |
| EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS | Other | Approved | Insulin Resistance | NOT_YET_RECRUITING | NCT06622616 |
| EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS | Other | Approved | Insulin Resistance | NOT_YET_RECRUITING | NCT06622616 |
| Treatment Package for First-Episode Depression | Drug | Preclinical | Depressive Disorder, Major | RECRUITING | NCT05616559 |
| Treatment Package for First-Episode Depression | Drug | Preclinical | Depressive Disorder, Major | RECRUITING | NCT05616559 |
| Treatment Package for First-Episode Depression | Drug | Preclinical | Depressive Disorder, Major | RECRUITING | NCT05616559 |
| Nivolumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT06034860 |
| MT-8421 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT06034860 |
| Nivolumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT06034860 |
| MT-8421 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT06034860 |
| LIAISON NES FLU A/B, RSV & COVID-19 | Other | Approved | Influenza a | RECRUITING | NCT06672692 |
| LIAISON NES FLU A/B, RSV & COVID-19 | Other | Approved | Influenza a | RECRUITING | NCT06672692 |
| MT-6402 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04795713 |
| MT-6402 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04795713 |
| Prospective monitoring of a large variety of parameters | Other | Preclinical | Chronic Obstructive Pulmonary Disease | ACTIVE_NOT_RECRUITING | NCT04140097 |
| Prospective monitoring of a large variety of parameters | Other | Preclinical | Chronic Obstructive Pulmonary Disease | ACTIVE_NOT_RECRUITING | NCT04140097 |
| Conventional fat grafting | Other | Phase PHASE1 | Romberg Disease | RECRUITING | NCT05610878 |
| Curcumin-preconditioned ASCs enrichment fat grafting | Other | Phase PHASE1 | Romberg Disease | RECRUITING | NCT05610878 |
| Cultured ASCs enrichment fat grafting | Other | Phase PHASE1 | Romberg Disease | RECRUITING | NCT05610878 |
| Conventional fat grafting | Other | Phase PHASE1 | Romberg Disease | RECRUITING | NCT05610878 |
| Curcumin-preconditioned ASCs enrichment fat grafting | Other | Phase PHASE1 | Romberg Disease | RECRUITING | NCT05610878 |
| Cultured ASCs enrichment fat grafting | Other | Phase PHASE1 | Romberg Disease | RECRUITING | NCT05610878 |
| PRP + ASCs injection | Other | Phase PHASE1 | Diabetic Foot Ulcer | RECRUITING | NCT05610865 |
| PRP + SVF injection | Other | Phase PHASE1 | Diabetic Foot Ulcer | RECRUITING | NCT05610865 |
| Only PRP injection | Other | Phase PHASE1 | Diabetic Foot Ulcer | RECRUITING | NCT05610865 |
| Control; Standard-of-care management | Other | Phase PHASE1 | Diabetic Foot Ulcer | RECRUITING | NCT05610865 |
| PRP + ASCs injection | Other | Phase PHASE1 | Diabetic Foot Ulcer | RECRUITING | NCT05610865 |
| PRP + SVF injection | Other | Phase PHASE1 | Diabetic Foot Ulcer | RECRUITING | NCT05610865 |
| Only PRP injection | Other | Phase PHASE1 | Diabetic Foot Ulcer | RECRUITING | NCT05610865 |
| Control; Standard-of-care management | Other | Phase PHASE1 | Diabetic Foot Ulcer | RECRUITING | NCT05610865 |
| General dietary recommendations | Other | Approved | Diet Interventions | RECRUITING | NCT06758817 |
| MedDiet+ intervention | Other | Approved | Diet Interventions | RECRUITING | NCT06758817 |
| General dietary recommendations | Other | Approved | Diet Interventions | RECRUITING | NCT06758817 |
| MedDiet+ intervention | Other | Approved | Diet Interventions | RECRUITING | NCT06758817 |
| Magnetic Resonance Imaging (MRI) and Breath test | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| Questionnaire completion | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| Blood, stool and saliva collection | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| Magnetic Resonance Imaging (MRI) and Breath test | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| Questionnaire completion | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| Blood, stool and saliva collection | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| Magnetic Resonance Imaging (MRI) and Breath test | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| Questionnaire completion | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| Blood, stool and saliva collection | Other | Preclinical | Sucrase Isomaltase Deficiency | NOT_YET_RECRUITING | NCT06770907 |
| MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen) | Drug | Phase PHASE1 | Advanced Malignant Solid Tumor | TERMINATED | NCT05098405 |
| MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen) | Drug | Phase PHASE1 | Advanced Malignant Solid Tumor | TERMINATED | NCT05098405 |
| Natural history study | Other | Preclinical | Age-Related Macular Degeneration | COMPLETED | NCT05963646 |
| Natural history study | Other | Preclinical | Age-Related Macular Degeneration | COMPLETED | NCT05963646 |
| Observational | Other | Phase PHASE1 | X-Linked Retinitis Pigmentosa | ACTIVE_NOT_RECRUITING | NCT04517149 |
| 4D-125 IVT Injection | Other | Phase PHASE1 | X-Linked Retinitis Pigmentosa | ACTIVE_NOT_RECRUITING | NCT04517149 |
| N-back Task | Other | Preclinical | Fibromyalgia | COMPLETED | NCT05910372 |
| Color Comparison Task | Other | Preclinical | Fibromyalgia | COMPLETED | NCT05910372 |
| N-back Task | Other | Preclinical | Fibromyalgia | COMPLETED | NCT05910372 |
| Color Comparison Task | Other | Preclinical | Fibromyalgia | COMPLETED | NCT05910372 |
| Fasting and Plant-Based Diet | Other | Approved | Psoriasis Arthritis | RECRUITING | NCT06905028 |
| Fasting and Plant-Based Diet | Other | Approved | Psoriasis Arthritis | RECRUITING | NCT06905028 |
| Observational | Other | Preclinical | Breast Cancer | RECRUITING | NCT04625023 |
| Observational | Other | Preclinical | Breast Cancer | RECRUITING | NCT04625023 |
| Observational | Other | Preclinical | Breast Cancer | RECRUITING | NCT04625023 |
| [18F]-PI2620 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT04715750 |
| [18F]-PI2620 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT04715750 |
| 4D-110 | Other | Phase PHASE1 | Choroideremia | ACTIVE_NOT_RECRUITING | NCT04483440 |
| 4D-110 | Other | Phase PHASE1 | Choroideremia | ACTIVE_NOT_RECRUITING | NCT04483440 |
| Adjuvant Atezolizumab-Bevacizumab Therapy | Drug | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT05516628 |
| Surgical Resection | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT05516628 |
| Adjuvant Atezolizumab-Bevacizumab Therapy | Drug | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT05516628 |
| Surgical Resection | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT05516628 |
| Standard of Care (SOC): Clinician's Standard Practice | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT06369220 |
| cobas® liat CT/NG/MG nucleic acid test | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT06369220 |
| Standard of Care (SOC): Clinician's Standard Practice | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT06369220 |
| cobas® liat CT/NG/MG nucleic acid test | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT06369220 |
| Standard of Care (SOC): Clinician's Standard Practice | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT06369220 |
| cobas® liat CT/NG/MG nucleic acid test | Other | Approved | Chlamydia Trachomatis Infection | COMPLETED | NCT06369220 |
| Hologic Aptima BV Assay | Other | Preclinical | Bacterial Vaginosis | COMPLETED | NCT06975436 |
| Cepheid Xpert Xpress MVP | Other | Preclinical | Bacterial Vaginosis | COMPLETED | NCT06975436 |
| BD Max™ Vaginal Panel | Other | Preclinical | Bacterial Vaginosis | COMPLETED | NCT06975436 |
| cobas® BV/CV test | Other | Preclinical | Bacterial Vaginosis | COMPLETED | NCT06975436 |
| Hologic Aptima BV Assay | Other | Preclinical | Bacterial Vaginosis | COMPLETED | NCT06975436 |
| Cepheid Xpert Xpress MVP | Other | Preclinical | Bacterial Vaginosis | COMPLETED | NCT06975436 |
| BD Max™ Vaginal Panel | Other | Preclinical | Bacterial Vaginosis | COMPLETED | NCT06975436 |
| cobas® BV/CV test | Other | Preclinical | Bacterial Vaginosis | COMPLETED | NCT06975436 |
| Diagnostic test | Other | Preclinical | Brain Tumor | RECRUITING | NCT06501521 |
| Diagnostic test | Other | Preclinical | Brain Tumor | RECRUITING | NCT06501521 |
| Primaquine | Other | Phase PHASE3 | Vivax Malaria | RECRUITING | NCT06148792 |
| Tafenoquine | Other | Phase PHASE3 | Vivax Malaria | RECRUITING | NCT06148792 |
| Primaquine | Other | Phase PHASE3 | Vivax Malaria | RECRUITING | NCT06148792 |
| Tafenoquine | Other | Phase PHASE3 | Vivax Malaria | RECRUITING | NCT06148792 |
| Primaquine | Other | Phase PHASE3 | Vivax Malaria | RECRUITING | NCT06148792 |
| Tafenoquine | Other | Phase PHASE3 | Vivax Malaria | RECRUITING | NCT06148792 |
| Disulfiram | Other | Phase PHASE2 | Breast Neoplasm Female | RECRUITING | NCT03323346 |
| Disulfiram | Other | Phase PHASE2 | Breast Neoplasm Female | RECRUITING | NCT03323346 |
| Optical coherence tomography (OCT) | Other | Preclinical | Retinal Dystrophies | RECRUITING | NCT05294978 |
| Optical coherence tomography (OCT) | Other | Preclinical | Retinal Dystrophies | RECRUITING | NCT05294978 |
| 18F-FDG | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Positron Emission Tomography | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Gallium Ga 68-labeled PSMA-11 | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Gallium Ga 68 FAPi-46 | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Computed Tomography | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| 18F-FDG | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Positron Emission Tomography | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Gallium Ga 68-labeled PSMA-11 | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Gallium Ga 68 FAPi-46 | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Computed Tomography | Other | Phase EARLY_PHASE1 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT04147494 |
| Nab-paclitaxel | Other | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Durvalumab | Other | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Ceralasertib | Other | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Nab-paclitaxel | Other | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Durvalumab | Other | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Ceralasertib | Other | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Observation | Other | Preclinical | Colorectal Cancer | RECRUITING | NCT05101382 |
| Observation | Other | Preclinical | Colorectal Cancer | RECRUITING | NCT05101382 |
| Observation | Other | Preclinical | Colorectal Cancer | RECRUITING | NCT04120935 |
| Observation | Other | Preclinical | Colorectal Cancer | RECRUITING | NCT04120935 |
| Observation | Other | Preclinical | Colorectal Cancer | RECRUITING | NCT04120935 |
| Fat-rich (HF) | Other | Approved | Metabolic Response to Dietary Modification | COMPLETED | NCT02487576 |
| Carbohydrate-rich (HC) | Other | Approved | Metabolic Response to Dietary Modification | COMPLETED | NCT02487576 |
| Fat-rich (HF) | Other | Approved | Metabolic Response to Dietary Modification | COMPLETED | NCT02487576 |
| Carbohydrate-rich (HC) | Other | Approved | Metabolic Response to Dietary Modification | COMPLETED | NCT02487576 |
| Panitumumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Pertuzumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Trastuzumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Ipilimumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Nivolumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Irinotecan | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Temozolomide | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Fluorouracil | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Folinic acid | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Capecitabine | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Oxaliplatin | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Panitumumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Pertuzumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Trastuzumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Ipilimumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Nivolumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Irinotecan | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Temozolomide | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Fluorouracil | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Folinic acid | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Capecitabine | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Oxaliplatin | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Panitumumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Pertuzumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Trastuzumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Ipilimumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Nivolumab | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Irinotecan | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Temozolomide | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Fluorouracil | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Folinic acid | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Capecitabine | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Oxaliplatin | Other | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer (CRC) | NOT_YET_RECRUITING | NCT06734156 |
| No intervention: observational study | Other | Preclinical | Colorectal Cancer (CRC) | NOT_YET_RECRUITING | NCT06734156 |
| MSC-Derived Secretome + Autologous PRGF | Other | Phase EARLY_PHASE1 | Osteoarthritis (OA) | NOT_YET_RECRUITING | NCT07157891 |
| MSC-Derived Secretome | Other | Phase EARLY_PHASE1 | Osteoarthritis (OA) | NOT_YET_RECRUITING | NCT07157891 |
| MSC-Derived Secretome + Autologous PRGF | Other | Phase EARLY_PHASE1 | Osteoarthritis (OA) | NOT_YET_RECRUITING | NCT07157891 |
| MSC-Derived Secretome | Other | Phase EARLY_PHASE1 | Osteoarthritis (OA) | NOT_YET_RECRUITING | NCT07157891 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | NOT_YET_RECRUITING | NCT07158905 |
| AV-1980R 180 µg | Other | Phase PHASE1 | Alzheimer Disease | NOT_YET_RECRUITING | NCT07158905 |
| AV-1980R 60 µg | Other | Phase PHASE1 | Alzheimer Disease | NOT_YET_RECRUITING | NCT07158905 |
| AV-1980R 20 µg | Other | Phase PHASE1 | Alzheimer Disease | NOT_YET_RECRUITING | NCT07158905 |
| Placebo | Other | Phase PHASE2 | Mild Alzheimer's Disease | NOT_YET_RECRUITING | NCT07178678 |
| NeuroEPO | Other | Phase PHASE2 | Mild Alzheimer's Disease | NOT_YET_RECRUITING | NCT07178678 |
| Placebo | Other | Phase PHASE2 | Mild Alzheimer's Disease | NOT_YET_RECRUITING | NCT07178678 |
| NeuroEPO | Other | Phase PHASE2 | Mild Alzheimer's Disease | NOT_YET_RECRUITING | NCT07178678 |
| TRE: Time-restricted eating | Other | Approved | Vaccination | RECRUITING | NCT07000708 |
| TRE: Time-restricted eating | Other | Approved | Vaccination | RECRUITING | NCT07000708 |
| Aflibercept IVT | Other | Phase PHASE2 | Diabetic Macular Edema | ACTIVE_NOT_RECRUITING | NCT05930561 |
| 4D-150 IVT | Other | Phase PHASE2 | Diabetic Macular Edema | ACTIVE_NOT_RECRUITING | NCT05930561 |
| Aflibercept IVT | Other | Phase PHASE2 | Diabetic Macular Edema | ACTIVE_NOT_RECRUITING | NCT05930561 |
| 4D-150 IVT | Other | Phase PHASE2 | Diabetic Macular Edema | ACTIVE_NOT_RECRUITING | NCT05930561 |
| Placebo (Adjuvant only) | Other | Phase PHASE1 | Alzheimer Disease | NOT_YET_RECRUITING | NCT07142278 |
| DUVAX 400 µg | Other | Phase PHASE1 | Alzheimer Disease | NOT_YET_RECRUITING | NCT07142278 |
| DUVAX 200 µg | Other | Phase PHASE1 | Alzheimer Disease | NOT_YET_RECRUITING | NCT07142278 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| Race and ethnicity | Other | Preclinical | Genetic Predisposition to Disease | RECRUITING | NCT04427163 |
| Health status | Other | Preclinical | Genetic Predisposition to Disease | RECRUITING | NCT04427163 |
| Blood sample analysis | Other | Preclinical | Genetic Predisposition to Disease | RECRUITING | NCT04427163 |
| [68Ga]Ga DOTA-5G | Other | Phase PHASE1 | Metastatic Lobular Breast Carcinoma | RECRUITING | NCT07020806 |
| [68Ga]Ga DOTA-5G | Other | Phase PHASE1 | Metastatic Lobular Breast Carcinoma | RECRUITING | NCT07020806 |
| Self sampling by Evalyn Brush home or in GP´s clinic | Other | Approved | Cervical Cancer | RECRUITING | NCT04226313 |
| Self-sampling by Evalyn Brush | Other | Approved | Cervical Cancer | RECRUITING | NCT04226313 |
| Self sampling by Evalyn Brush home or in GP´s clinic | Other | Approved | Cervical Cancer | RECRUITING | NCT04226313 |
| Self-sampling by Evalyn Brush | Other | Approved | Cervical Cancer | RECRUITING | NCT04226313 |
| ATL-001 (Ciclopirox oral solution) | Other | Phase PHASE1 | Congenital Erythropoietic Porphyria (CEP) | RECRUITING | NCT07024316 |
| ATL-001 (Ciclopirox oral solution) | Other | Phase PHASE1 | Congenital Erythropoietic Porphyria (CEP) | RECRUITING | NCT07024316 |
| MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients | Drug | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML | Drug | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 with Obinutuzumab pretreatment | Drug | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax | Other | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A | Drug | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 | Drug | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| Famotidine 400 mg/50 mL | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT05084521 |
| Famotidine 400 mg/50 mL | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT05084521 |
| donor-derived cell-free DNA test | Other | Preclinical | Kidney Transplant Rejection | RECRUITING | NCT07060716 |
| donor-derived cell-free DNA test | Other | Preclinical | Kidney Transplant Rejection | RECRUITING | NCT07060716 |
| [18F]florbetaben | Other | Phase PHASE3 | Cardiac Amyloidosis | RECRUITING | NCT05184088 |
| [18F]florbetaben | Other | Phase PHASE3 | Cardiac Amyloidosis | RECRUITING | NCT05184088 |
| Lutetium-177 Octreotate | Other | Approved | Neuroendocrine Tumors | ACTIVE_NOT_RECRUITING | NCT02743741 |
| Lutetium-177 Octreotate | Other | Approved | Neuroendocrine Tumors | ACTIVE_NOT_RECRUITING | NCT02743741 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04828161 |
| ensovibep | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04828161 |
| Spirometry | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| Vital signs | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| LDCT | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| Blood sampling | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| Exhaled breath condensate sampling | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| Spirometry | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| Vital signs | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| LDCT | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| Blood sampling | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| Exhaled breath condensate sampling | Other | Approved | Lung Cancer | RECRUITING | NCT06016569 |
| Arm B - Diagnostic test: HPV detection in liquid biopsies | Other | Preclinical | Cervical Cancer | RECRUITING | NCT05774561 |
| Arm A - Diagnostic test: HPV detection in liquid biopsies | Other | Preclinical | Cervical Cancer | RECRUITING | NCT05774561 |
| Arm B - Diagnostic test: HPV detection in liquid biopsies | Other | Preclinical | Cervical Cancer | RECRUITING | NCT05774561 |
| Arm A - Diagnostic test: HPV detection in liquid biopsies | Other | Preclinical | Cervical Cancer | RECRUITING | NCT05774561 |
| Aflibercept IVT | Other | Phase PHASE1 | Neovascular (Wet) Age-Related Macular Degeneration | RECRUITING | NCT05197270 |
| 4D-150 IVT | Other | Phase PHASE1 | Neovascular (Wet) Age-Related Macular Degeneration | RECRUITING | NCT05197270 |
| Aflibercept IVT | Other | Phase PHASE1 | Neovascular (Wet) Age-Related Macular Degeneration | RECRUITING | NCT05197270 |
| 4D-150 IVT | Other | Phase PHASE1 | Neovascular (Wet) Age-Related Macular Degeneration | RECRUITING | NCT05197270 |
| Self-sampling of the urogenital area | Other | Approved | Oropharynx Cancer | RECRUITING | NCT07033091 |
| Blood sampling | Other | Approved | Oropharynx Cancer | RECRUITING | NCT07033091 |
| Self-sampling by gargling kit at home | Other | Approved | Oropharynx Cancer | RECRUITING | NCT07033091 |
| Questionnaire | Other | Approved | Oropharynx Cancer | RECRUITING | NCT07033091 |
| Self-sampling by gargling kit at dental clinic | Other | Approved | Oropharynx Cancer | RECRUITING | NCT07033091 |
| Race and ethnicity | Other | Preclinical | Genetic Predisposition to Disease | RECRUITING | NCT04427163 |
| Health status | Other | Preclinical | Genetic Predisposition to Disease | RECRUITING | NCT04427163 |
| Blood sample analysis | Other | Preclinical | Genetic Predisposition to Disease | RECRUITING | NCT04427163 |
| No Intervention: Observational Cohort | Other | Preclinical | Suicide Attempt | RECRUITING | NCT07422090 |
| No Intervention: Observational Cohort | Other | Preclinical | Suicide Attempt | RECRUITING | NCT07422090 |
| pembrolizumab (treatment) | Drug | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03519412 |
| temozolomide (induction), | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03519412 |
| Long-Chain Fatty Acid (LCFA) | Other | Approved | Medium-chain Acyl-CoA Dehydrogenase Deficiency | RECRUITING | NCT06623032 |
| Medium-Chain Fatty Acid (MCFA) | Other | Approved | Medium-chain Acyl-CoA Dehydrogenase Deficiency | RECRUITING | NCT06623032 |
| Long-Chain Fatty Acid (LCFA) | Other | Approved | Medium-chain Acyl-CoA Dehydrogenase Deficiency | RECRUITING | NCT06623032 |
| Medium-Chain Fatty Acid (MCFA) | Other | Approved | Medium-chain Acyl-CoA Dehydrogenase Deficiency | RECRUITING | NCT06623032 |
| 4D-710 | Other | Phase PHASE2 | Cystic Fibrosis Lung | RECRUITING | NCT05248230 |
| 4D-710 | Other | Phase PHASE2 | Cystic Fibrosis Lung | RECRUITING | NCT05248230 |
| 4D-710 | Other | Phase PHASE2 | Cystic Fibrosis Lung | RECRUITING | NCT05248230 |
| 4D-710 | Other | Phase PHASE2 | Cystic Fibrosis Lung | RECRUITING | NCT05248230 |
| Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos | Other | Approved | IVF | RECRUITING | NCT04619524 |
| Cervical mucus will be collected from patients undergoing IVF | Other | Approved | IVF | RECRUITING | NCT04619524 |
| Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos | Other | Approved | IVF | RECRUITING | NCT04619524 |
| Cervical mucus will be collected from patients undergoing IVF | Other | Approved | IVF | RECRUITING | NCT04619524 |
| Proteomic analysis of exhaled breath condensate | Other | Preclinical | Acute Respiratory Failure | RECRUITING | NCT06189924 |
| Proteomic analysis of exhaled breath condensate | Other | Preclinical | Acute Respiratory Failure | RECRUITING | NCT06189924 |
| Collection of breath condensate | Other | Preclinical | Bronchial Asthma | RECRUITING | NCT04157361 |
| Collection of breath condensate | Other | Preclinical | Bronchial Asthma | RECRUITING | NCT04157361 |
| Single Photon Emission Computed Tomography | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Questionnaire Administration | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| PSMA PET-CT Scan | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Lutetium Lu 177 Vipivotide Tetraxetan | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Computed Tomography | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Bone Scan | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Biospecimen Collection | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Other | Phase PHASE3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06864988 |
| 4D-150 IVT (3E10 vg/eye) | Other | Phase PHASE3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06864988 |
| Hydrogen-Oxygen Ultrafine Bubbles | Other | Phase PHASE1 | Healthy Volunteer | NOT_YET_RECRUITING | NCT07357909 |
| Hydrogen-Oxygen Ultrafine Bubbles | Other | Phase PHASE1 | Healthy Volunteer | NOT_YET_RECRUITING | NCT07357909 |
| Gemcitabine + Cisplatin + Durvalumab | Other | Phase PHASE2 | Advanced Biliary Tract Carcinoma | RECRUITING | NCT07036380 |
| CT-Scan | Other | Phase PHASE2 | Advanced Biliary Tract Carcinoma | RECRUITING | NCT07036380 |
| MP0317 + Gemcitabine + Cisplatine + Durvalumab | Other | Phase PHASE2 | Advanced Biliary Tract Carcinoma | RECRUITING | NCT07036380 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05642429 |
| AV-1959D | Other | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05642429 |
| [203Pb]Pb-MP0712 | Other | Phase PHASE1 | Large Cell Neuroendocrine Carcinoma | RECRUITING | NCT07278479 |
| [212Pb]Pb-MP0712 | Other | Phase PHASE1 | Large Cell Neuroendocrine Carcinoma | RECRUITING | NCT07278479 |
| Florbetaben F18 | Other | Phase PHASE1 | Cardiac Amyloidosis | RECRUITING | NCT06790394 |
| Florbetaben F18 | Other | Phase PHASE1 | Cardiac Amyloidosis | RECRUITING | NCT06790394 |
| [⁶⁸Ga]Ga-PSMA PET/CT with Delayed Pelvic PET-Only Acquisition | Other | Preclinical | Treatment-naive Prostate Cancer | RECRUITING | NCT07531329 |
| [⁶⁸Ga]Ga-PSMA PET/CT with Delayed Pelvic PET-Only Acquisition | Other | Preclinical | Treatment-naive Prostate Cancer | RECRUITING | NCT07531329 |
| time-restricted feeding in a 5:2 regimen | Other | Approved | Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD) | RECRUITING | NCT07530809 |
| time-restricted feeding in a 5:2 regimen | Other | Approved | Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD) | RECRUITING | NCT07530809 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| 4D-150 IVT (3E10 vg/eye) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| 4D-150 IVT (3E10 vg/eye) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| 4D-150 IVT (3E10 vg/eye) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | NOT_YET_RECRUITING | NCT07285993 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| [18F]PI-2620 | Other | Phase PHASE3 | Alzheimer Disease | RECRUITING | NCT05641688 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| OraQuick | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| DPP HIV-Syphilis test system | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| Cepheid GeneXpert HIV-1 Qual POC HIV VL test | Other | Approved | HIV Infections | COMPLETED | NCT04793750 |
| PET/CT | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| 18F-FDG | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| 18F-FAPI-74 | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT07285993 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| 4D-150 IVT (3E10 vg/eye) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| 4D-150 IVT (3E10 vg/eye) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| 4D-150 IVT (3E10 vg/eye) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| Florbetaben F18 | DRUG | Phase PHASE1 | Cardiac Amyloidosis | RECRUITING | NCT06790394 |
| [203Pb]Pb-MP0712 | OTHER | Phase PHASE1 | Large Cell Neuroendocrine Carcinoma | RECRUITING | NCT07278479 |
| [212Pb]Pb-MP0712 | DRUG | Phase PHASE1 | Large Cell Neuroendocrine Carcinoma | RECRUITING | NCT07278479 |
| Gemcitabine + Cisplatin + Durvalumab | DRUG | Phase PHASE2 | Advanced Biliary Tract Carcinoma | RECRUITING | NCT07036380 |
| CT-Scan | PROCEDURE | Phase PHASE2 | Advanced Biliary Tract Carcinoma | RECRUITING | NCT07036380 |
| MP0317 + Gemcitabine + Cisplatine + Durvalumab | DRUG | Phase PHASE2 | Advanced Biliary Tract Carcinoma | RECRUITING | NCT07036380 |
| Questionnaire | OTHER | Approved | Oropharynx Cancer | RECRUITING | NCT07033091 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | BIOLOGICAL | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| 4D-150 IVT (3E10 vg/eye) | BIOLOGICAL | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | NCT07064759 |
| Single Photon Emission Computed Tomography | PROCEDURE | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| PSMA PET-CT Scan | PROCEDURE | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Magnetic Resonance Imaging | PROCEDURE | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Lutetium Lu 177 Vipivotide Tetraxetan | DRUG | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Computed Tomography | PROCEDURE | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Bone Scan | PROCEDURE | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Biospecimen Collection | PROCEDURE | Phase PHASE2 | Metastatic Castration-Resistant Prostate Carcinoma | RECRUITING | NCT06526299 |
| Panitumumab | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Pertuzumab | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Trastuzumab | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Ipilimumab | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Irinotecan | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Temozolomide | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Fluorouracil | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Folinic acid | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Primaquine | DRUG | Phase PHASE3 | Vivax Malaria | RECRUITING | NCT06148792 |
| Tafenoquine | DRUG | Phase PHASE3 | Vivax Malaria | RECRUITING | NCT06148792 |
| MT-8421 | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT06034860 |
| N-back Task | OTHER | Preclinical | Fibromyalgia | COMPLETED | NCT05910372 |
| Color Comparison Task | OTHER | Preclinical | Fibromyalgia | COMPLETED | NCT05910372 |
| Remdesivir | BIOLOGICAL | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780463 |
| MP0420 | DRUG | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780463 |
| Atezolizumab | DRUG | Phase PHASE2 | Small Cell Lung Carcinoma | NOT_YET_RECRUITING | NCT05703997 |
| Longevity Diet (LD) + Fasting-mimicking Diet (FMD) | BEHAVIORAL | Approved | Overweight | UNKNOWN | NCT05698654 |
| Fasting-mimicking diet (FMD) | BEHAVIORAL | Approved | Overweight | UNKNOWN | NCT05698654 |
| MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients | DRUG | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML | DRUG | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 with Obinutuzumab pretreatment | DRUG | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax | DRUG | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A | DRUG | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 | DRUG | Phase PHASE1 | Leukemia | RECRUITING | NCT05673057 |
| Nab-paclitaxel | DRUG | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Durvalumab | DRUG | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Ceralasertib | DRUG | Phase PHASE2 | Triple Negative Breast Cancer Metastatic | RECRUITING | NCT05582538 |
| Radioactive Tablet (Part 2 Only) | OTHER | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05476107 |
| AMT-126 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05476107 |
| Amino Acid Solution | OTHER | Phase PHASE1 | Neuroendocrine Tumors | RECRUITING | NCT05475210 |
| 177Lu-DOTA-EB-TATE | DRUG | Phase PHASE1 | Neuroendocrine Tumors | RECRUITING | NCT05475210 |
| Niraparib | DRUG | Phase PHASE2 | Metastatic Colorectal Cancer | WITHDRAWN | NCT05412706 |
| 4D-710 | BIOLOGICAL | Phase PHASE2 | Cystic Fibrosis Lung | RECRUITING | NCT05248230 |
| Aflibercept IVT | BIOLOGICAL | Phase PHASE2 | Diabetic Macular Edema | ACTIVE_NOT_RECRUITING | NCT05930561 |
| 4D-150 IVT | BIOLOGICAL | Phase PHASE2 | Diabetic Macular Edema | ACTIVE_NOT_RECRUITING | NCT05930561 |
| 99mTc-Duramycin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05177640 |
| Booster vaccine | BIOLOGICAL | Phase PHASE3 | SARS CoV 2 Infection | UNKNOWN | NCT05148845 |
| Nilotinib BE 112 mg | DRUG | Phase PHASE3 | Alzheimer Disease | NOT_YET_RECRUITING | NCT05143528 |
| Nilotinib BE 84mg | DRUG | Phase PHASE3 | Alzheimer Disease | NOT_YET_RECRUITING | NCT05143528 |
| MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen) | DRUG | Phase PHASE1 | Advanced Malignant Solid Tumor | TERMINATED | NCT05098405 |
| MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen) | DRUG | Phase PHASE1 | Advanced Malignant Solid Tumor | TERMINATED | NCT05098405 |
| Convalescent plasma treatment | BIOLOGICAL | Phase PHASE2 | COVID-19 | UNKNOWN | NCT04873414 |
| Ensovibep | DRUG | Phase PHASE1 | COVID-19 | TERMINATED | NCT04870164 |
| Glucagon | DRUG | Approved | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT04859322 |
| ensovibep | DRUG | Phase PHASE2 | Covid19 | COMPLETED | NCT04834856 |
| MT-6402 | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04795713 |
| 89Zr-trastuzumab | DRUG | Phase PHASE2 | HER2-positive Solid Tumor | WITHDRAWN | NCT04757090 |
| AMT-101 (oral)-Dose B | DRUG | Phase PHASE2 | Pouchitis | COMPLETED | NCT04741087 |
| AMT-101 (oral)-Dose A | DRUG | Phase PHASE2 | Pouchitis | COMPLETED | NCT04741087 |
| 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | DRUG | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | DRUG | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | DRUG | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule | DRUG | Phase PHASE1 | Type1 Diabetes | COMPLETED | NCT04625595 |
| Placebo (oral) | OTHER | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT05372939 |
| AMT-101 (oral) | DRUG | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT05372939 |
| 4D-310 | BIOLOGICAL | Phase PHASE1 | Fabry Disease | RECRUITING | NCT05629559 |
| Observational | OTHER | Preclinical | Breast Cancer | RECRUITING | NCT04625023 |
| 4D-125 IVT Injection | BIOLOGICAL | Phase PHASE1 | X-Linked Retinitis Pigmentosa | ACTIVE_NOT_RECRUITING | NCT04517149 |
| 4D-110 | BIOLOGICAL | Phase PHASE1 | Choroideremia | ACTIVE_NOT_RECRUITING | NCT04483440 |
| FOLFIRI | DRUG | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT04259944 |
| Capecitabine | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| CAPOX | DRUG | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT04259944 |
| Preoperative chemotherapy | DRUG | Phase PHASE2 | Triple-negative Breast Cancer | UNKNOWN | NCT04248998 |
| Metformin | DRUG | Phase PHASE2 | Triple-negative Breast Cancer | UNKNOWN | NCT04248998 |
| Placebos | DRUG | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT04224857 |
| AMT-101 | DRUG | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT04224857 |
| Cabozantinib 60 MG | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | UNKNOWN | NCT04131543 |
| Cabozantinib 40 MG | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | UNKNOWN | NCT04131543 |
| Cabozantinib 20 MG | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | UNKNOWN | NCT04131543 |
| fulvestrant | DRUG | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT04115306 |
| PMD-026 | DRUG | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| MP0310 | DRUG | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04049903 |
| MT-5111 (experimental study drug) | DRUG | Phase PHASE1 | HER2-positive Solid Cancers | TERMINATED | NCT04029922 |
| MT-0169 | DRUG | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT04017130 |
| Fasting Mimicking diet | OTHER | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT03811587 |
| Nivolumab | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Propranolol | DRUG | Phase PHASE2 | Cerebral Cavernous Malformation | COMPLETED | NCT03589014 |
| pembrolizumab (treatment) | BIOLOGICAL | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03519412 |
| temozolomide (induction), | DRUG | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03519412 |
| Oxaliplatin | DRUG | Phase PHASE3 | Colon Cancer Stage II | RECRUITING | NCT06490536 |
| Gemcitabine | DRUG | Phase PHASE2 | Non-hodgkin Lymphoma,B Cell | TERMINATED | NCT03488251 |
| Multicomponent training | OTHER | Approved | Aging | COMPLETED | NCT03455179 |
| High-speed resistance training | OTHER | Approved | Aging | COMPLETED | NCT03455179 |
| Slow-speed traditional resistance training | OTHER | Approved | Aging | COMPLETED | NCT03455179 |
| MP0250 plus BOR+DEX | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma in Relapse | COMPLETED | NCT03136653 |
| MP0274 | DRUG | Phase PHASE1 | Neoplasms | COMPLETED | NCT03084926 |
| Observation | OTHER | Preclinical | Colorectal Cancer | RECRUITING | NCT05101382 |
| Ultratrace Iobenguane I131 | DRUG | Preclinical | Pheochromocytoma | APPROVED_FOR_MARKETING | NCT02961491 |
| 99mTc-MIP-1404 Injection | DRUG | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT02615067 |
| MT-3724 | DRUG | Phase PHASE2 | Non-hodgkin Lymphoma | TERMINATED | NCT03645395 |
| dalcetrapib | DRUG | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT02525939 |
| MT-3724 Phase 2 | DRUG | Phase PHASE1 | Non-Hodgkin's B-cell Lymphoma | TERMINATED | NCT02361346 |
| MT-3724 Phase 1 | DRUG | Phase PHASE1 | Non-Hodgkin's B-cell Lymphoma | TERMINATED | NCT02361346 |
| Dihydroartemisinin-Piperaquine | DRUG | Preclinical | Plasmodium Falciparum Infection | COMPLETED | NCT02353494 |
| Intra-Articular Hyaluronic Acid | DEVICE | Approved | Osteoarthritis Of Knee | UNKNOWN | NCT02280538 |
| AX-024.HCl | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02243683 |
| Pfs25 VLP- FhCMB | BIOLOGICAL | Phase PHASE1 | Malaria | COMPLETED | NCT02013687 |
| rosuvastatin | DRUG | Phase PHASE2 | Obstructive Coronary Artery Disease | COMPLETED | NCT01837823 |
| Drug: 99mTc-MIP-1404 | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01667536 |
| Positron Emission Tomography (PET) /Computerized tomography (CT) | PROCEDURE | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| 124I-MIBG (carrier added) | DRUG | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added) | DRUG | Phase EARLY_PHASE1 | Neuroblastoma | TERMINATED | NCT01583842 |
| 123I-MIP-1072 | DRUG | Preclinical | Prostate Cancer | WITHDRAWN | NCT01279785 |
| methylprednisolone | DRUG | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| mycophenolate mofetil | DRUG | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | COMPLETED | NCT00891306 |
| LY2127399 | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00689507 |
| Iodofiltic acid I 123 | DRUG | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00514501 |
| PA83-FhCMB | BIOLOGICAL | Phase PHASE1 | Anthrax | COMPLETED | NCT02239172 |
| MP0250 | DRUG | Phase PHASE1 | Neoplasms | COMPLETED | NCT02194426 |
| Liraglutide | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT02092896 |
| Nilvadipine | DRUG | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT02017340 |
| Sodium Acetate C11 PET/CT Imaging | DRUG | Phase PHASE2 | Gliomas | WITHDRAWN | NCT01961934 |
| 99mTc-MIP-1404 | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01654874 |
| C11-Sodium Acetate | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01530269 |
| Sodium Acetate C11 | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01304485 |
| 99mTc MIP 1405 | RADIATION | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01261754 |
| 99mTc MIP 1404 | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01615406 |
| Saline | OTHER | Phase PHASE1 | Healthy | COMPLETED | NCT01250795 |
| HAI-05 Influenza Vaccine | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01250795 |
| HAC1 Vaccine | BIOLOGICAL | Phase PHASE1 | H1N1 Flu | COMPLETED | NCT01177202 |
| cyclosporine | DRUG | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Mycophenolate mofetil | DRUG | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Alipogene Tiparvovec (AMT-011), Human LPL [S447X] | GENETIC | Phase PHASE2 | Familial Lipoprotein Lipase Deficiency | UNKNOWN | NCT01109498 |
| Placebo | DRUG | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780463 |
| Retinoic Acid | DRUG | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT01048086 |
| Blood draw | OTHER | Preclinical | Parkinson Disease | UNKNOWN | NCT01005030 |
| 111-In capromab pendetide | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00992745 |
| Ultratrace Iobenguane I 131 | DRUG | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT00992173 |
| Fluciclatide Injection | DRUG | Phase PHASE2 | Solid Tumors | COMPLETED | NCT00918281 |
| Ultratrace® Iobenguane I131 | RADIATION | Phase PHASE2 | Pheochromocytoma | UNKNOWN | NCT00874614 |
| 131-I-MIP-1145 | DRUG | Phase PHASE1 | Metastatic Melanoma | TERMINATED | NCT00747825 |
| 123-I-MIP-1095 | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00712829 |
| 123-I-MIP-1072 | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00992745 |
| 90Y-SMT487 | DRUG | Phase PHASE2 | Malignant Carcinoid Tumor | WITHDRAWN | NCT00696930 |
| UltratraceTM Iobenguane I 131 Therapy | DRUG | Phase PHASE2 | Neuroblastoma | COMPLETED | NCT00659984 |
| UltratraceTM Iobenguane I 131 Imaging | DRUG | Phase PHASE2 | Neuroblastoma | COMPLETED | NCT00659984 |
| 99mTc-glucarate solution | DRUG | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00614354 |
| Ultratrace Iobenguane (MIBG) I 131 | DRUG | Phase PHASE1 | Pheochromocytoma | COMPLETED | NCT00458952 |
| Ultratrace iobenguane I 131 | DRUG | Phase PHASE1 | Pheochromocytoma | COMPLETED | NCT00339131 |
| MP0112 | BIOLOGICAL | Phase PHASE1 | Wet Age-Related Macular Degeneration | TERMINATED | NCT01086761 |
Total products: 1379